

¹

Doctoral Thesis

²

Microbiota in Human Diseases

³

Jaewoong Lee

⁴

Department of Biomedical Engineering

⁵

Ulsan National Institute of Science and Technology

⁶

2025

⁷

Microbiota in Human Diseases

⁸

Jaewoong Lee

⁹

Department of Biomedical Engineering

¹⁰

Ulsan National Institute of Science and Technology



CHURCH OF THE FLYING SPAGHETTI MONSTER

February 09, 2021

Letter of Good Standing

Dear Sir or Madam:

I am pleased to verify that _____

JAEWOONG LEE

is an ordained minister of the Church of the Flying Spaghetti Monster and recognized
within our organization as a member in good standing.

We hereby consent to this minister performing ceremonies and request that they are
granted all privileges and respect appropriate to a spiritual leader.

Any questions can be directed to the undersigned.

A handwritten signature in black ink that reads "Bobby Henderson".

Representative,
Church of the Flying Spaghetti Monster
Bobby Henderson



CHURCH OF THE FLYING SPAGHETTI MONSTER

February 09, 2021

Letter of Good Standing

Dear Sir or Madam:

I am pleased to verify that _____

JAEWOONG LEE

is an ordained minister of the Church of the Flying Spaghetti Monster and recognized
within our organization as a member in good standing.

We hereby consent to this minister performing ceremonies and request that they are
granted all privileges and respect appropriate to a spiritual leader.

Any questions can be directed to the undersigned.

A handwritten signature in black ink that reads "Bobby Henderson".

Representative,
Church of the Flying Spaghetti Monster
Bobby Henderson

13

Abstract

14 (Microbiome)

15 (PTB) Section 2 introduces...

16 (Periodontitis) Section 3 describes...

17 (Colon) Setion 4...

18 (Conclusion)

19

20 **This doctoral dissertation is an addition based on the following papers that the author has already
21 published:**

- 22 • Hong, Y. M., **Lee, Jaewoong**, Cho, D. H., Jeon, J. H., Kang, J., Kim, M. G., ... & Kim, J. K. (2023).
23 Predicting preterm birth using machine learning techniques in oral microbiome. *Scientific Reports*,
24 13(1), 21105.

Contents

| | | | |
|----|-------|---|----|
| 26 | 1 | Introduction | 2 |
| 27 | 2 | Predicting preterm birth using random forest classifier in salivary microbiome | 6 |
| 28 | 2.1 | Introduction | 6 |
| 29 | 2.2 | Materials and methods | 8 |
| 30 | 2.2.1 | Study design and study participants | 8 |
| 31 | 2.2.2 | Clinical data collection and grouping | 8 |
| 32 | 2.2.3 | Salivary microbiome sample collection | 8 |
| 33 | 2.2.4 | 16s rRNA gene sequencing | 9 |
| 34 | 2.2.5 | Bioinformatics analysis | 9 |
| 35 | 2.2.6 | Data and code availability | 9 |
| 36 | 2.3 | Results | 10 |
| 37 | 2.3.1 | Overview of clinical information | 10 |
| 38 | 2.3.2 | Comparison of salivary microbiomes composition | 10 |
| 39 | 2.3.3 | Random forest classification to predict PTB risk | 10 |
| 40 | 2.4 | Discussion | 18 |
| 41 | 3 | Random forest prediction model for periodontitis statuses based on the salivary microbiomes | 20 |
| 42 | 3.1 | Introduction | 20 |
| 43 | 3.2 | Materials and methods | 22 |
| 44 | 3.2.1 | Study participants enrollment | 22 |
| 45 | 3.2.2 | Periodontal clinical parameter diagnosis | 22 |
| 46 | 3.2.3 | Saliva sampling and DNA extraction procedure | 24 |
| 47 | 3.2.4 | Bioinformatics analysis | 24 |
| 48 | 3.2.5 | Data and code availability | 25 |
| 49 | 3.3 | Results | 26 |

| | | | |
|----|---------------------------|---|----|
| 50 | 3.3.1 | Summary of clinical information and sequencing data | 26 |
| 51 | 3.3.2 | Diversity indices reveal differences among the periodontitis severities . | 26 |
| 52 | 3.3.3 | DAT among multiple periodontitis severities and their correlation . . . | 26 |
| 53 | 3.3.4 | Classification of periodontitis severities by random forest models . . . | 27 |
| 54 | 3.4 | Discussion | 47 |
| 55 | 4 | Colon microbiome | 51 |
| 56 | 4.1 | Introduction | 51 |
| 57 | 4.2 | Materials and methods | 52 |
| 58 | 4.3 | Results | 53 |
| 59 | 4.4 | Discussion | 54 |
| 60 | 5 | Conclusion | 55 |
| 61 | References | | 56 |
| 62 | Acknowledgments | | 65 |

63

List of Figures

| | | | |
|----|----|--|----|
| 64 | 1 | DAT volcano plot | 12 |
| 65 | 2 | Salivary microbiome compositions over DAT | 13 |
| 66 | 3 | Random forest-based PTB prediction model | 14 |
| 67 | 4 | Diversity indices | 15 |
| 68 | 5 | PROM-related DAT | 16 |
| 69 | 6 | Validation of random forest-based PTB prediction model | 17 |
| 70 | 7 | Diversity indices | 33 |
| 71 | 8 | Differentially abundant taxa (DAT) | 34 |
| 72 | 9 | Correlation heatmap | 35 |
| 73 | 10 | Random forest classification metrics | 36 |
| 74 | 11 | Random forest classification metrics from external datasets | 37 |
| 75 | 12 | Rarefaction curves for alpha-diversity indices | 38 |
| 76 | 13 | Salivary microbiome compositions in the different periodontal statuses | 39 |
| 77 | 14 | Correlation plots for differentially abundant taxa | 40 |
| 78 | 15 | Clinical measurements by the periodontitis statuses | 41 |
| 79 | 16 | Number of read counts by the periodontitis statuses | 42 |
| 80 | 17 | Proportion of DAT | 43 |

| | | | |
|----|----|--|----|
| 81 | 18 | Random forest classification metrics with the full microbiome compositions and ANCOM-selected DAT compositions | 44 |
| 82 | | | |
| 83 | 19 | Alpha-diversity indices account for evenness | 45 |
| 84 | 20 | Gradient Boosting classification metrics | 46 |

List of Tables

| | | | |
|----|---|---|----|
| 86 | 1 | Confusion matrix | 4 |
| 87 | 2 | Standard clinical information of study participants | 11 |
| 88 | 3 | Clinical characteristics of the study subjects | 28 |
| 89 | 4 | Feature combinations and their evaluations | 29 |
| 90 | 5 | List of DAT among the periodontally healthy and periodontitis stages | 30 |
| 91 | 6 | Feature the importance of taxa in the classification of different periodontal statuses. | 31 |
| 92 | 7 | Beta-diversity pairwise comparisons on the periodontitis statuses | 32 |

93

List of Abbreviations

- 94 **ACC** Accuracy
95 **ASV** Amplicon sequence variant
96 **AUC** Area-under-curve
97 **BA** Balanced accuracy
98 **C-section** Cesarean section
99 **DAT** Differentially abundant taxa
100 **F1** F1 score
101 **Faith PD** Faith's phylogenetic diversity
102 **FTB** Full-term birth
103 **GA** Gestational age
104 **MWU test** Mann-Whitney U-test
105 **PRE** Precision
106 **PROM** Prelabor rupture of membrane
107 **PTB** Preterm birth
108 **ROC curve** Receiver-operating characteristics curve
109 **rRNA** Ribosomal RNA
110 **SD** Standard deviation
111 **SEN** Sensitivity
112 **SPE** Specificity
113 **t-SNE** t-distributed stochastic neighbor embedding

¹¹⁴ 1 Introduction

¹¹⁵ The microbiome refers to the complex community of microorganisms, including bacteria, viruses, fungi,
¹¹⁶ and other microbes, that inhabit various environment within living organisms (Ursell, Metcalf, Parfrey,
¹¹⁷ & Knight, 2012; Gilbert et al., 2018). In humans, the microbiome plays a crucial role in maintaining
¹¹⁸ health (Lloyd-Price, Abu-Ali, & Huttenhower, 2016), influencing processes such as digestion (Lim, Park,
¹¹⁹ Tong, & Yu, 2020), immune response (Thaiss, Zmora, Levy, & Elinav, 2016; Kogut, Lee, & Santin, 2020;
¹²⁰ C. H. Kim, 2018), and even mental health (Mayer, Tillisch, Gupta, et al., 2015; X. Zhu et al., 2017;
¹²¹ X. Chen, D'Souza, & Hong, 2013). These microbial communities are not static nor constant, but rather
¹²² dynamic ecosystem that interacts with their host and respond to environmental changes. Recent studies
¹²³ have revealed that imbalances in the microbiome, known as dysbiosis, can contribute to a wide range of
¹²⁴ diseases, including obesity (John & Mullin, 2016; Tilg, Kaser, et al., 2011; Castaner et al., 2018), diabetes
¹²⁵ (Barlow, Yu, & Mathur, 2015; Hartstra, Bouter, Bäckhed, & Nieuwdorp, 2015; Sharma & Tripathi, 2019),
¹²⁶ infections (Whiteside, Razvi, Dave, Reid, & Burton, 2015; Alverdy, Hyoju, Weigerinck, & Gilbert, 2017),
¹²⁷ inflammatory conditions (Francescone, Hou, & Grivennikov, 2014; Peirce & Alviña, 2019; Honda &
¹²⁸ Littman, 2012), and cancers (Helmink, Khan, Hermann, Gopalakrishnan, & Wargo, 2019; Cullin, Antunes,
¹²⁹ Straussman, Stein-Thoeringer, & Elinav, 2021; Sepich-Poore et al., 2021; Schwabe & Jobin, 2013). Thus,
¹³⁰ understanding the composition of the human microbiomes is essential for developing new therapeutic
¹³¹ approaches that target these microbial populations to promote health and prevent diseases.

¹³² (Brain-gut axis)

¹³³ 16S ribosomal RNA (rRNA) gene sequencing is one of the most extensively applied methods for
¹³⁴ characterizing microbial communities by targeting the conserved 16S rRNA gene, which contains both
¹³⁵ highly conserved and variable regions in bacteria (Tringe & Hugenholtz, 2008; Janda & Abbott, 2007).
¹³⁶ The conserved regions enable universal primer binding, while the variable regions provide the specificity
¹³⁷ needed to differentiate microbial taxa. Among these regions, the V3-V4 region is frequently selected for
¹³⁸ sequencing due to its balance between phylogenetic resolution and sequencing efficiency (Johnson et al.,
¹³⁹ 2019). Therefore, the V3-V4 region offers sufficient variability to classify a wide range of bacteria taxa
¹⁴⁰ while maintaining compatibility with widely used sequencing platforms.

¹⁴¹ Diversity indices are essential techniques for evaluating the complexity and variety of microbial
¹⁴² communities, in ecological and microbiological research (Tucker et al., 2017; Hill, 1973). Alpha-diversity
¹⁴³ index attributes to the heterogeneity within a specific community, obtaining the number of different taxa
¹⁴⁴ and the distribution of taxa among the individuals, i.e., richness and evenness. On the other hand, beta-
¹⁴⁵ diversity index measures the variations in microbiome compositions between the individuals, highlighting
¹⁴⁶ differences among the microbiome compositions of the study participants. Altogether, by providing a
¹⁴⁷ thorough understanding of microbiome compositions, diversity indices, e.g. alpha-diversity and beta-
¹⁴⁸ diversity, allow us to investigate factors that affecting community variability and structure.

¹⁴⁹ (DAT selection)

¹⁵⁰ Classification is one of the supervised machine learning techniques used to categorized data into
¹⁵¹ predefined classes based on features within the data. In other words, the method learns the relationship

152 between input features and their corresponding output classes through the process of training a classifica-
153 tion model using labeled data. Classification models are essential for advising choices in a wide range of
154 applications, including medical diagnostics. Thus, researchers could uncover sophisticated connections in
155 input features and corresponding classes and produce reliable prediction by utilizing machine learning
156 classification.

157 Random forest classification is one of the ensemble machine learning methods that constructs several
158 decision trees during training and aggregates their results to provide classification predictions (Breiman,
159 2001). A portion of the features and classes—known as bootstrapping (Jiang & Simon, 2007; Champagne,
160 McNairn, Daneshfar, & Shang, 2014; J.-H. Kim, 2009) and feature bagging (Bryll, Gutierrez-Osuna, &
161 Quek, 2003; Alelyani, 2021; Yaman & Subasi, 2019)—are utilized to construct each tree in the forest. The
162 majority vote from each tree determines the final classification, which lowers the possibility of overfitting
163 in comparison to a single decision tree. Furthermore, random forest classifier offers several advantages,
164 including its robustness to outliers and its ability to calculate the feature importance.

165 Evaluating the performance of a machine learning classification model is essential to ensure its
166 reliability and effectiveness in real-world solutions and applications. A confusion matrix is a tabular
167 representation of predictions of classification, showing the counts of true positives (TP), true negatives
168 (TN), false positives (FP), and false negatives (FN) (Table 1). From this matrix, evaluations can be derived:
169 accuracy (ACC; Equation 1), balanced accuracy (BA; Equation 2), F1 score (F1; Equation 3), sensitivity
170 (SEN; Equation 4), specificity (SPE; Equation 5), and precision (PRE; Equation 6). These metrics are in
171 [0, 1] range and high metrics are good metrics. The confusion matrix also helps in identifying specific
172 types of errors, such as a tendency to produce false positive or false negatives, offering valuable insights
173 for improving the classification model. By combining the confusion matrix with other evaluation metrics,
174 researchers can comprehensively assess the classification metrics and refine it for real-world solutions
175 and applications.

176 (AUC)

177 (Limitation & Novelty)

Table 1: Confusion matrix

| | | Predicted | |
|--------|----------|---------------------|---------------------|
| | | Positive | Negative |
| Actual | Positive | True positive (TP) | False negative (FN) |
| | Negative | False positive (FP) | True negative (TN) |

178

$$\text{ACC} = \frac{\text{TP} + \text{TN}}{\text{TP} + \text{FN} + \text{FP} + \text{TN}} \quad (1)$$

179

$$\text{BA} = \frac{1}{2} \times \left(\frac{\text{TP}}{\text{TP} + \text{FP}} + \frac{\text{TN}}{\text{TN} + \text{FN}} \right) \quad (2)$$

180

$$\text{F1} = \frac{2 \times \text{TP}}{2 \times \text{TP} + \text{FP} + \text{FN}} \quad (3)$$

181

$$\text{SEN} = \frac{\text{TP}}{\text{TP} + \text{FP}} \quad (4)$$

182

$$\text{SPE} = \frac{\text{TN}}{\text{TN} + \text{FN}} \quad (5)$$

$$\text{PRE} = \frac{\text{TP}}{\text{TP} + \text{FP}} \quad (6)$$

183 **2 Predicting preterm birth using random forest classifier in salivary mi-**
184 **crobiome**

185 **This section includes the published contents:**

186 Hong, Y. M., **Lee, Jaewoong**, Cho, D. H., Jeon, J. H., Kang, J., Kim, M. G., ... & Kim, J. K. (2023).
187 Predicting preterm birth using machine learning techniques in oral microbiome. *Scientific Reports*, 13(1),
188 21105.

189 **2.1 Introduction**

190 Preterm birth (PTB), characterized by the delivery of neonates prior to 37 weeks of gestation, is one
191 of the major cause to neonatal mortality and morbidity (Blencowe et al., 2012). Multiple pregnancies
192 including twins, short cervical length, and infection on genitourinary tract are known risk factor for
193 PTB (Goldenberg, Culhane, Iams, & Romero, 2008). Nevertheless, the extent to which these aspects
194 affect birth outcomes is still up for debate. Henceforth, strategies to boost gestation and enhance delivery
195 outcomes can be more conveniently implemented when pregnant women at high risk of PTB are identified
196 early (Iams & Berghella, 2010).

197 Prediction models that can be utilized as a foundation for intervention methods still have an unac-
198 ceptable amount of classification evaluations, including accuracy, sensitivity, and specificity, despite a
199 great awareness of the risk factors that trigger PTB (Sotiriadis, Papatheodorou, Kavvadias, & Makrydi-
200 mas, 2010). Several attempts have been made to predict PTB through integrating data such as human
201 microbiome composition, inflammatory markers, and prior clinical data with predictive machine learn-
202 ing methods (Berghella, 2012). Because it is affordable and straightforward to use, fetal fibronectin is
203 commonly used in medical applications. However, with a sensitivity of only 56% that merely similar to
204 random prediction, it has a low classification evaluation (Honest et al., 2009). Due to the difficulty and
205 imprecision of the method in general, as well as the requirement for a qualified specialist cervical length
206 measuring is also restricted (Leitich & Kaider, 2003).

207 Preterm prelabor rupture of membranes (PROM) brought on by gestational inflammation and infection
208 contribute to about 70% of PTB cases (Romero, Dey, & Fisher, 2014). Nevertheless, as antibiotics and
209 anti-inflammatory therapeutic strategies were ineffective to decrease PTB occurrence rates, the pathology
210 of PTB has not been entirely elucidated by inflammatory and infectious pathways (Romero, Hassan, et al.,
211 2014). Recent researches on maternal microbiomes were beginning to examine unidentified connections
212 of PTB as a consequence of developmental processes in molecular biological technology (Fettweis et al.,
213 2019).

214 However, as anti-inflammatory and antibiotic therapies were insufficient to lower PTB occurrence
215 rates, infectious and inflammatory processes are insufficient to exhaustively clarify the pathogenesis and
216 pathophysiology of PTB. It has been hypothesized that the microbiota linked to PTB originate from either
217 a hematogenous pathway or the female genitourinary tract increasing through the vagina and/or cervix.
218 (Han & Wang, 2013). Vaginal microbiome compositions have been found in women who eventually

219 acquire PTB, and recent studies have tried to predict PTB risk using cervico-vaginal fluid (Kindinger et
220 al., 2017). Even though previous investigation have confirmed the potential relationships between the
221 vaginal microbiome compositions and PTB, these studies are only able to clarify an upward trajectory.

222 Multiple unfavorable birth outcomes, including PROM and PTB, have been linked to periodontitis
223 as an independence risk factor, according to numerous epidemiological researches (Offenbacher et al.,
224 1996). It is expected that the oral microbiome will be able to explain additional hematogenous pathways
225 in light of these precedents; however, the oral microbiome composition of fetuses is limited understood.

226 Hence, in order to identify the salivary microbiome linked to PTB and to establish a machine learning
227 prediction model of PTB determined by oral microbiome compositions, this study examined the salivary
228 microbiome compositions of PTB study participants with a full-term birth (FTB) study participants.

229 **2.2 Materials and methods**

230 **2.2.1 Study design and study participants**

231 Between 2019 and 2021, singleton pregnant women who received treatment to Jeonbuk National University Hospital for childbirth were the participants of this study. This study was conducted according to the
232 Declaration of Helsinki (Goodyear, Krleza-Jeric, & Lemmens, 2007). The Institutional Review Board
233 authorized this study (IRB file No. 2019-01-024). Participants who were admitted for elective cesarean
234 sections (C-sections) or induction births, as well as those who had written informed consent obtained
235 with premature labor or PROM, were eligible.
236

237 **2.2.2 Clinical data collection and grouping**

238 Questionnaires and electronic medical records were implemented to gather information on both previous
239 and current pregnancy outcomes. The following clinical data were analyzed:

- 240 • maternal age at delivery
- 241 • diabetes mellitus
- 242 • hypertension
- 243 • overweight and obesity
- 244 • C-section
- 245 • history PROM or PTB
- 246 • gestational week on delivery
- 247 • birth weight
- 248 • sex

249 **2.2.3 Salivary microbiome sample collection**

250 Salivary microbiome samples were collected 24 hours before to delivery using mouthwash. The standard
251 methods of sterilizing were performed. Medical experts oversaw each stage of the sample collecting
252 procedure. Participants received instruction not to eat, drink, or brush their teeth for 30 minutes before
253 sampling salivary microbiome. Saliva samples were gathered by washing the mouth for 30 seconds with
254 12 mL of a mouthwash solution (E-zen Gargle, JN Pharm, Pyeongtaek, Gyeonggi, Korea). The samples
255 were tagged with the anonymous ID for each participant and kept at 4 °C until they underwent further
256 processing. Genomic DNA was extracted using an ExgeneTM Clinic SV kit (GeneAll Biotechnology,
257 Seoul, Korea) following with the manufacturer instructions and store at -20 °C.

258 **2.2.4 16s rRNA gene sequencing**

259 Salivary microbiome samples were transported to the Department of Biomedical Engineering of the
260 Ulsan National Institute of Science and Technology . 16S rRNA sequencing was then carried out using a
261 commissioned Illumina MiSeq Reagent Kit v3 (Illumina, San Diego, CA, USA). Library methods were
262 utilized to amplify the V3-V4 areas. 300 base-pair paired-end reads were produced by sequencing the
263 pooled library using a v3 \times 600 cycle chemistry after the samples had been diluted to a final concentration
264 of 6 pM with a 20% PhiX control.

265 **2.2.5 Bioinformatics analysis**

266 The independent *t*-test was utilized to evaluate the differences of continuous values between from the
267 PTB participants than the FTB participants; χ^2 -square test was applied to decide statistical differences of
268 categorical values. Clinical measurement comparisons were conducted using SPSS (version 20.0) (Spss
269 et al., 2011). At $p < 0.05$, statistical significance was taken into consideration.

270 QIIME2 (version 2022.2) was implemented to import 16S rRNA gene sequences from salivary
271 microbiome samples of study participants for additional bioinformatics processing (Bolyen et al., 2019).
272 DADA2 was used to verify the qualities of raw sequences (Callahan et al., 2016). The remain sequences
273 were clustered into amplicon sequence variants (ASVs). Diversity indices, namely Faith PD for alpha
274 diversity index (Faith, 1992) and Hamming distance for beta diversity index (Hamming, 1950), were
275 calculated. MWU test (Mann & Whitney, 1947), and PERMANOVA multivariate test were evaluated for
276 measuring statistical significance (Anderson, 2014; Kelly et al., 2015).

277 Taxonomic assignment were implemented with HOMD (version 15.22) (T. Chen et al., 2010).
278 Afterward, DESeq2 was implemented to identify differentially abundant taxa (DAT) that could distinguish
279 between salivary microbiome from PTB and FTB participants (Love, Huber, & Anders, 2014). Taxa with
280 $|\log_2 \text{FoldChange}| > 1$ and $p < 0.05$ were considered as statistically significant.

281 The taxa for predicting PTB using salivary microbiome data were determined using a random forest
282 classifier (Breiman, 2001). Through stratified *k*-fold cross-validation (*k* = 5) that preserves the existence
283 rate of PTB and FTB participants, consistency and trustworthy classification were ensured (Wong & Yeh,
284 2019).

285 **2.2.6 Data and code availability**

286 All sequences from the 59 study participants have been added to the Sequence Read Archives (project
287 ID PRJNA985119): <https://dataview.ncbi.nlm.nih.gov/object/PRJNA985119?reviewer=6fdj2e9c8gp9vtf52n330e2h8j>. Docker image that employed throughout this study is available in the
288 DockerHub: https://hub.docker.com/r/fumire/helixco_premature. Every code used in this
289 study can be found on GitHub: https://github.com/CompbioLabUnist/Helixco_Premature.

291 **2.3 Results**

292 **2.3.1 Overview of clinical information**

293 In the beginning, 69 volunteer mothers were recruited for this study. However, due to insufficient clinical
294 information or twin pregnancies, 10 participants were excluded from the study participants. Demographic
295 and clinical information of the study participants are displayed in Table 2. Because PROM is one of the
296 leading factors of PTB, it was prevalent in the PTB group than the FTB group. Other maternal clinical
297 factors did not significantly differ between the FTB and PTB groups. There were no cases in both groups
298 that had a history of simultaneous periodontal disease or cigarette smoking.

300 **2.3.2 Comparison of salivary microbiomes composition**

301 The salivary microbiome composition was composed of 13953804 sequences from 59 study participants,
302 with 102305.95 ± 19095.60 and 64823.41 ± 15841.65 (mean \pm SD) reads/sample before and following
303 the quality-check stage, accordingly. There was not a significant distinction between the PTB and FTB
304 groups with regard to on alpha diversity nor beta diversity metrics (Figure 4).

305 DESeq2 was used to select 32 DAT that distinguish between the PTB and FTB groups out of the 465
306 species that were examined (Love et al., 2014): 26 FTB-enriched DAT and six PTB-enriched DAT. Seven
307 PROM-related DAT were removed from these 32 PTB-related DAT to lessen the confounding effect of
308 PROM (Figure 5). Therefore, there were a total of 25 PTB-related DAT: 22 FTB-enriched DAT and three
309 PTB-enriched DAT (Figure 1).

310 A significant negative correlation was found using Pearson correlation analysis between GW and
311 differences between PTB-enriched DAT and FTB-enriched DAT ($r = -0.542$ and $p = 7.8e-6$; Figure 5).

312 **2.3.3 Random forest classification to predict PTB risk**

313 To classify PTB according to DAT, random forest classifiers were constructed. The nine most significant
314 DAT were used to obtain the best BA (0.765 ± 0.071 ; Figure 3a). Moreover, random forest classification
315 model determined each DAT's importance (Figure 3b). We conducted a validation procedure on nine
316 twin pregnancies that were excluded in the initial study design in order to confirm the reliability and
317 dependability of our random forest-based PTB prediction model (Figure 6). Comparable to the PTB
318 prediction model on the 59 initial singleton study participants, the validation classification on PTB risk of
these twin participants have an accuracy of 87.5%.

Table 2: Standard clinical information of study participants.

Continuous variable for independent *t*-test. Categorical variable for Pearson's χ^2 -square test. Continuous variable: mean \pm SD. Categorical variable: count (proportion)

| | PTB (n=30) | FTB (n=29) | p-value |
|------------------------------|--------------------|--------------------|--------------|
| Maternal age (years) | 31.8 \pm 5.2 | 33.7 \pm 4.5 | 0.687 |
| C-section | 20 (66.7%) | 24 (82.7%) | 0.233 |
| Previous PTB history | 4 (13.3%) | 1 (3.4%) | 0.353 |
| PROM | 12 (40.0%) | 1 (3.4%) | 0.001 |
| Pre-pregnant overweight | 8 (26.7%) | 7 (24.1%) | 1.000 |
| Gestational weight gain (kg) | 9.0 \pm 5.9 | 11.5 \pm 4.6 | 0.262 |
| Diabetes | 2 (6.7%) | 2 (6.9%) | 1.000 |
| Hypertension | 11 (36.7%) | 4 (13.8%) | 0.072 |
| Gestational age (weeks) | 32.5 \pm 3.4 | 38.3 \pm 1.1 | \leq 0.001 |
| Birth weight (g) | 1973.4 \pm 686.6 | 3283.4 \pm 402.7 | \leq 0.001 |
| Male | 14 (46.7%) | 13 (44.8%) | 1.000 |




Figure 1: DAT volcano plot.

Red dots represent PTB-enriched DAT, while green dots represent FTB-enriched DAT.




Figure 2: **Salivary microbiome compositions over DAT.**

(a) Frequencies of DAT of study subjects. The study participants are arranged in respect of (PTB-enriched DAT – FTB-enriched DAT). The study participants' GA is displayed in accordance with the upper panel's order (PTB: red bar, FTB: green bar. PROM: arrow head.) **(b)** Correlation plot with GA and (PTB-enriched DAT – FTB-enriched DAT). Strong negative correlation is found with Pearson correlation.




Figure 3: **Random forest-based PTB prediction model.**

(a) Machine learning evaluations upon number of features (DAT). Random Forest classifier has the best BA (0.765 ± 0.071 ; Mean \pm SD) with the nine most important DAT. **(b)** Importance of DAT.




Figure 4: **Diversity indices.**

(a) Alpha diversity index (Faith PD). There is no statistically significant difference between the PTB and FTB group (MWU test $p = 0.46$). **(b)** t-SNE plot with beta diversity index (Hamming distance). There is no statistically significant difference between the PTB and FTB group (PERMANOVA test $p = 0.908$)




Figure 5: **PROM-related DAT**.

Only seven of these 42 PROM-related DAT overlapped with PTB-related DAT (bold text). Blue dots represented PROM-underrepresented DAT, while red dots represented PROM-overrepresented DAT.




Figure 6: Validation of random forest-based PTB prediction model.

Nine twin pregnancies (eight PTB subjects and a FTB subject) that were excluded in the initial study subjects were subjected to a validation procedure. The random forest-based PTB prediction model shows 87.5% accuracy, comparable to the PTB classification evaluations on the singleton study subjects (0.714 ± 0.061 . Mean \pm SD)

319 **2.4 Discussion**

320 In this study, we employed salivary microbiome compositions to develop the random forest-based PTB
321 prediction models to estimate PTB risks. Previous reports have indicated bidirectional associations
322 between pregnancy outcomes and salivary microbiome compositions (Han & Wang, 2013). Nevertheless,
323 the salivary microbiome composition is not yet elucidated. Salivary microbial dysbiosis, including gingival
324 inflammation and periodontitis, have been connected to unfavorable pregnancy outcomes, such as PTB
325 (Ide & Papapanou, 2013). However, the techniques utilized in recent research that primarily focus on
326 recognized infections have led to inconsistent outcomes.

327 One of the most common salivary taxa that has been examined is *Fusobacterium nucleatum* (Han,
328 2015; Brennan & Garrett, 2019; Bolstad, Jensen, & Bakken, 1996), that is a Gram-negative, anaerobic, and
329 filamentous bacteria. *Fusobacterium nucleatum* can be separated from not only the salivary microbiome
330 but also the vaginal microbiome (Vander Haar, So, Gyamfi-Bannerman, & Han, 2018; Witkin, 2019). In
331 both animal and human investigation, *Fusobacterium nucleatum* infection has been linked to risk of PTB
332 (Doyle et al., 2014). According to recent researches, the placenta women who give birth prematurely may
333 include additional salivary microbiome dysbiosis, such as *Bergeyella* spp. and *Porphyromonas gingivalis*
334 (León et al., 2007; Katz, Chegini, Shiverick, & Lamont, 2009). Although *Bergeyella* spp. were one of the
335 PROM-overrepresented DAT (Figure 5), it was excluded in the final 25 PTB-related DAT. Furthermore,
336 *Porphyromonas gingivalis* and *Campylobacter gracilis* were pathogens of periodontitis in sub-gingival
337 microbiome (Yang et al., 2022). *Lactobacillus gasseri* was also one of the FTB-enriched DAT (Figure
338 1), and it is well established that early PTB risk can be reduced by *Lactobacillus gasseri* in the vaginal
339 microbiome (Basavaprabhu, Sonu, & Prabha, 2020; Payne et al., 2021).

340 With DAT comprising 22 FTB-enriched DAT and three PTB-enriched DAT (Figure 1), we discovered
341 that the FTB study participants had the majority of the essential DAT that distinguished between the PTB
342 and FTB groups. Thus, we hypothesize that the pathogenesis and pathophysiology of PTB may have been
343 triggered by an absence of species with protective characteristics. The association between unfavorable
344 pregnancy outcomes and a dysfunctional microbiome has been explained through two distinct processes.
345 According to the first hypothesis, periodontal pathogens originating in the gingival biofilm might spread
346 from the infected salivary microbiome over the placenta microbiome, invade the intra-amniotic fluid
347 and fetal circulation, and then have a direct impact on the fetoplacental unit, leading to bacteremia
348 (Hajishengallis, 2015). Based on the second hypothesis, inflammatory mediators and endotoxins that
349 generated by the sub-gingival inflammation and derived from dental plaque of periodontitis may spread
350 throughout the body and reach the fetoplacental unit (Stout et al., 2013; Aagaard et al., 2014). Despite
351 belonging to the same species, some subgroups of the salivary microbiome may influence pregnancy
352 outcomes in both favorable and adverse manners. Following this line of argumentation, the salivary
353 microbiome composition or their dysbiosis are more significant than the existence of particular bacteria.

354 Notably, microbial alteration that take place throughout pregnancy may be expected results of a healthy
355 pregnancy. Those pregnancy-related vulnerabilities to dental problem like periodontitis can be explained
356 by three factors. Because of hormone-driven gingival hyper-reactivity to the salivary microbiome in the

357 oral biofilm including sub-gingival biofilm, these conditions are prevalent in pregnant women. For insight
358 at the relationship between the salivary microbiome compositions and PTB, further studies with pathway
359 analysis are warranted.

360 Our study confirmed that salivary microbiome composition could provide potential biomarkers for
361 predicting pregnancy complications including PTB risks using random forest-based classification models,
362 despite a limited number of study participants and a tiny validation sample size. Another limitation of
363 our study was 16S rRNA sequencing. In other words, unlike the shotgun sequencing, 16S rRNA gene
364 sequencing only focused on bacteria, not viruses nor fungi. We did not delve into other variables like
365 nutrition status and socioeconomic statuses of study participants that might affect the salivary microbiome
366 composition.

367 Notwithstanding these limitations, this prospective examination showed the promise of the random
368 forest-based PTB prediction models based on mouthwash-derived salivary microbiome composition.
369 Before applying the methods developed in this study in a clinical context, more multi-center and extensive
370 research is warranted to validate our findings.

371 **3 Random forest prediction model for periodontitis statuses based on the**
372 **salivary microbiomes**

373 **This section includes the published contents:**

374

375 **3.1 Introduction**

376 Saliva microbial dysbiosis brought on by the accumulation of plaque results in periodontitis, a chronic
377 inflammatory disease of the tissue that surrounds the tooth (Kinane, Stathopoulou, & Papapanou, 2017).
378 Loss of periodontal attachment is a consequence of periodontitis, which may lead to irreversible bone loss
379 and, eventually, permanent tooth loss if left untreated. A new classification criterion of periodontal diseases
380 was created in 2018, about 20 years after the 1999 statements of the previous one (Papapanou et al.,
381 2018). Even with this evolution, radiographic and clinical markers of periodontitis progression remain the
382 primary methods for diagnosing periodontitis (Papapanou et al., 2018). Such tools, nevertheless, frequently
383 demonstrate the prior damage from periodontitis rather than its present condition. Certain individuals have
384 a higher risk of periodontitis, a higher chance of developing severe generalized periodontitis, and a worse
385 response to common salivary bacteria control techniques utilized to prevent and treat periodontitis. As a
386 result, the 2017 framework for diagnosing periodontitis additionally allows for the potential development
387 of biomarkers to enhance diagnosis and treatment of periodontitis (Tonetti, Greenwell, & Kornman, 2018).
388 Instead of only depending on the progression of periodontitis, a new etiological indication based on the
389 current state must be introduced in order to enable appropriate intervention through early detection of
390 periodontitis. Thus, the current clinical diagnostic techniques that rely on periodontal probing can be
391 uncomfortable for patients with periodontitis (Canakci & Canakci, 2007).

392 Due to the development of salivaomics, in this manner, the examination of saliva has emerged as
393 a significant alternative to the conventional ways of identifying periodontitis (Altingöz et al., 2021;
394 Melguizo-Rodríguez, Costela-Ruiz, Manzano-Moreno, Ruiz, & Illescas-Montes, 2020). Given that saliva
395 sampling is non-invasive, painless, and accessible to non-specialists, it may be a valuable instrument for
396 diagnosing periodontitis (Zhang et al., 2016). Furthermore, much research has suggested that periodontitis
397 could be a trigger in the development and exacerbation of metabolic syndrome (Morita et al., 2010; Nesbitt
398 et al., 2010). Consequently, alteration in these levels of salivary microbiome markers may serve as high
399 effective diagnostic, prognostic, and therapeutic indicators for periodontitis and other systemic diseases
400 (Miller, Ding, Dawson III, & Ebersole, 2021; Čižmárová et al., 2022). The pathogenesis of periodontitis
401 typically comprises qualitative as well as quantitative alterations in the salivary microbial community,
402 despite that it is a complex disease impacted by a number of contributing factors including age, smoking
403 status, stress, and nourishment (Abusleme, Hoare, Hong, & Diaz, 2021; Lafaurie et al., 2022). Depending
404 on the severity of periodontitis, the salivary microbial community's diversity and characteristics vary
405 (Abusleme et al., 2021), indicating that a new etiological diagnostic standards might be microbial
406 community profiling based on clinical diagnostic criteria. As a consequence, salivary microbiome

407 compositions have been characterized in numerous research in connection with periodontitis. High-
408 throughput sequencing, including 16S rRNA gene sequencing, has recently used in multiple studies to
409 identify variations in the bacterial composition of sub-gingival plaque collections from periodontal healthy
410 individuals and patients with periodontitis (Altabtbaei et al., 2021; Iniesta et al., 2023; Nemoto et al., 2021).
411 This realization has rendered clear that alterations in the salivary microbial community—especially, shifts to
412 dysbiosis—are significant contributors to the pathogenesis and development of periodontitis (Lamont, Koo,
413 & Hajishengallis, 2018). Yet most of these research either focused only on the microbiome alterations in
414 sub-gingival plaque collection, comprised a limited number of periodontitis study participants, or did not
415 account for the impact of multiple severities of periodontitis.

416 For the objective of diagnosing periodontitis, previous research has developed machine learning-based
417 prediction models based on oral microbiome compositions, such as the sub-gingival microbial dysbiosis
418 index (T. Chen, Marsh, & Al-Hebshi, 2022; Chew, Tan, Chen, Al-Hebshi, & Goh, 2024), which have
419 demonstrated good diagnostic evaluation and could be applied to individual saliva collection. Despite
420 offering valuable details, these indicators are frequently restricted by their limited emphasis on classifying
421 the multiple severities of periodontitis. Furthermore, many of these machine learning models currently in
422 practice are trained solely upon the existence of periodontitis rather than on the multiple severities of
423 periodontitis.

424 Recently, we employed multiplex quantitative-PCR and machine learning-based classification model
425 to predict the severity of periodontitis based on the amount of nine pathogens of periodontitis from
426 saliva collections (E.-H. Kim et al., 2020). On the other hand, the fact that we focused merely at nine
427 pathogens for periodontitis and neglected the variety bacterial species associated to the various severities
428 of periodontitis constrained the breadth of our investigation. By developing a machine learning model
429 that could classify multiple severities of periodontitis based on the salivary microbiome composition,
430 this study aims to fill these knowledge gaps and produce more accurate and therapeutically useful
431 guidance to evaluate progression of periodontitis. Hence, in order to examine the salivary microbiome
432 composition of both healthy controls and patients with periodontitis in multiple stages, we applied
433 16S rRNA gene sequencing. Furthermore, employing the 2018 classification criteria, we sought to find
434 biomarkers (species) for the precise prediction of periodontitis severities (Papapanou et al., 2018; Chapple
435 et al., 2018).

436 **3.2 Materials and methods**

437 **3.2.1 Study participants enrollment**

438 Between 2018-08 and 2019-03, 250 study participants—100 healthy controls, 50 patients with stage I
439 periodontitis, 50 patients with stage II periodontitis, and 50 patients with stage III periodontitis—visited
440 visited the Department of Periodontics at Pusan National University Dental Hospital. The Institutional
441 Review Board of the Pusan National University Dental Hospital accepted this study protocol and design
442 (IRB No. PNUDH-2016-019). Every study participants provided their written informed authorization
443 after being fully informed about this study's objectives and methodologies. Exclusion criteria for the
444 study participants are followings:

- 445 1. People who, throughout the previous six months, underwent periodontal therapy, including root
446 planing and scaling.
- 447 2. People who struggle with systemic conditions that may affect periodontitis developments, such as
448 diabetes.
- 449 3. People who, throughout the previous three months, were prescribed anti-inflammatory medications
450 or antibiotics.
- 451 4. Women who were pregnant or breastfeeding.
- 452 5. People who have persistent mucosal lesions, e.g. pemphigus or pemphigoid, or acute infection, e.g.
453 herpetic gingivostomatitis.
- 454 6. Patient with grade C periodontitis or localized periodontitis (< 30% of teeth involved).

455 **3.2.2 Periodontal clinical parameter diagnosis**

456 A skilled periodontist conducted each clinical procedure. Six sites per tooth were used to quantify
457 gingival recession and probing depth: mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual,
458 and distolingual (Huang et al., 2007). A periodontal probe (Hu-Friedy, IL, USA) was placed parallel to
459 the major axis of the tooth at each tooth location in order to gather measurements. The cementoenamel
460 junction of the tooth was analyzed to determine the clinical attachment level, and the deepest point of
461 probing was taken to determine the periodontal pocket depth from the marginal gingival level of the
462 tooth. Plaque index was measured by probing four surfaces per tooth: mesial, distal, buccal, and palatal
463 or lingual. Plaque index was scored by the following criteria:

- 464 0. No plaque present.
- 465 1. A thin layer of plaque that adheres to the surrounding tissue of the tooth and free gingival margin.
466 Only through the use of a periodontal probe on the tooth surface can the plaque be existed.
- 467 2. Significant development of soft deposits that are visible within the gingival pocket, which is a
468 region between the tooth and gingival margin.

469 3. Considerable amount of soft matter on the tooth, the gingival margin, and the gingival pocket.

470 The arithmetic average of the plaque indices collected from every tooth was determined to calculate
471 plaque index of each study participant. By probing four surfaces per tooth, mesial, distal, buccal, and
472 palatal or lingual, to assess gingival bleeding, the gingival index was scored by the following criteria:

473 0. Normal gingiva: without inflammation nor discoloration.

474 1. Mild inflammation: minimal edema and slight color changes, but no bleeding on probing.

475 2. Moderate inflammation: edema, glazing, redness, and bleeding on probing.

476 3. Severe inflammation: significant edema, ulceration, redness, and spontaneous bleeding.

477 The arithmetic average of the gingival indices collected from every tooth was determined to calculate
478 gingival index of each study participant. The relevant data was not displayed, despite that furcation
479 involvement and bleeding on probing were thoroughly utilized into account during the diagnosis process.

480 Periodontitis was diagnosed in respect to the 2018 classification criteria (Papapanou et al., 2018;
481 Chapple et al., 2018). An experienced periodontist diagnosed the periodontitis severity by considering
482 complexity, depending on clinical examinations including radiographic images and periodontal probing.

483 Periodontitis is categorized into healthy, stage I, stage II, and stage III with the following criteria:

484 • Healthy:

485 1. Bleeding sites < 10%

486 2. Probing depth: \leq 3 mm

487 • Stage I:

488 1. No tooth loss because of periodontitis.

489 2. Inter-dental clinical attachment level at the site of the greatest loss: 1-2 mm

490 3. Radiographic bone loss: < 15%

491 • Stage II:

492 1. No tooth loss because of periodontitis.

493 2. Inter-dental clinical attachment level at the site of the greatest loss: 3-4 mm

494 3. Radiographic bone loss: 15-33%

495 • Stage III:

496 1. Teeth loss because of periodontitis: \leq teeth

497 2. Inter-dental clinical attachment level at the site of the greatest loss: \geq 5 mm

498 3. Radiographic bone loss: > 33%

499 **3.2.3 Saliva sampling and DNA extraction procedure**

500 All study participants received instructions to avoid eating, drinking, brushing, and using mouthwash for
501 at least an hour prior to the saliva sample collection process. These collections were conducted between
502 09:00 and 11:00. Mouth rinse was collected by rinsing the mouth for 30 seconds with 12 mL of a solution
503 (E-zen Gargle, JN Pharm, Korea). All saliva samples were tagged with anonymous ID and stored at -4 °C.

504 Bacteria DNA was extracted from saliva samples using an Exgene™Clinic SV DNA extraction kit
505 (GeneAll, Seoul, Korea), and quality and quantity of bacterial DNA was measured using a NanoDrop
506 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). Hyper-variable regions (V3-V4)
507 of the 16S rRNA gene were amplified using the following primer:

- 508 • Forward: 5' -TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNNGCWGCAG-3'
509 • Reverse: 5' -GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC-3'

510 The standard protocols of the Illumina 16S Metagenomic Sequencing Library Preparation were
511 followed in the preparation of the libraries. The PCR conditions were as follows:

- 512 1. Heat activation for 30 seconds at 95 °C.
513 2. 25 cycles for 30 seconds at 95 °C.
514 3. 30 seconds at 55 °C.
515 4. 30 seconds at 72 °C.

516 NexteraXT Indexed Primer was applied to amplification 10 µL of the purified initial PCR products for
517 the final library creation. The second PCR used the same conditions as the first PCR conditions but with
518 10 cycles. 16S rRNA gene sequencing was performed via 2×300 bp paired-end sequencing at Macrogen
519 Inc. (Macrogen, Seoul, Korea) using Illumina MiSeq platform (Illumina, San Diego, CA, USA).

520 **3.2.4 Bioinformatics analysis**

521 We computed alpha-diversity and beta-diversity indices to quantify the divergence of phylogenetic
522 information. Following alpha-diversity indices were calculated using the scikit-bio Python package
523 (version 0.5.5) (Rideout et al., 2018), and these alpha-diversity indices were compared using the MWU
524 test:

- 525 • Abundance-based Coverage Estimator (ACE) (Chao & Lee, 1992)
526 • Chao1 (Chao, 1984)
527 • Fisher (Fisher, Corbet, & Williams, 1943)
528 • Margalef (Magurran, 2021)
529 • Observed ASVs (DeSantis et al., 2006)
530 • Berger-Parker *d* (Berger & Parker, 1970)
531 • Gini index (Gini, 1912)

- 532 • Shannon (Weaver, 1963)
533 • Simpson (Simpson, 1949)

534 Aitchison index for a beta-diversity index was calculated using QIIME2 (version 2020.8) (Aitchison,
535 Barceló-Vidal, Martín-Fernández, & Pawlowsky-Glahn, 2000; Bolyen et al., 2019). We employed the
536 t-SNE algorithm to illustrate multi-dimensional data from the beta-diversity index computation (Van der
537 Maaten & Hinton, 2008). The beta-diversity index was compared using the PERMANOVA test (Anderson,
538 2014; Kelly et al., 2015) and MWU test.

539 DAT between multiple periodontitis stages were identified by ANCOM (Lin & Peddada, 2020). The
540 log-transformed absolute abundances of DAT were analyzed by hierarchical clustering in order to identify
541 sub-groups with similar abundance patterns on periodontitis severities. Additionally, we examined the
542 relative proportions among the 20 DAT in order to reduce the effect of salivary bacteria that differ
543 insignificantly across the multiple severities of periodontitis.

544 Differentially abundant taxa (DAT) among multiple periodontitis severities were selected from the
545 salivary microbiome compositions by ANCOM (Lin & Peddada, 2020). In contrast to conventional
546 techniques that examine raw abundance counts, ANCOM applies log-ratio between taxa to account for
547 the salivary microbiome composition data. The log-transformed abundances of DAT were subjected to
548 hierarchical clustering to discover subgroups of DAT with similar patterns on periodontitis severities.
549 Furthermore, we examined the relative proportion among the DAT in order to reduce the effects of other
550 salivary bacteria that differ non-significantly across the multiple periodontitis severities.

551 As previously stated (E.-H. Kim et al., 2020), we used stratified k -fold cross-validation ($k = 10$)
552 by severity of periodontitis to achieve consistent and trustworthy classification results (Wong & Yeh,
553 2019). Additionally, we utilized various features with confusion matrices and their derivations to evaluate
554 the classification outcomes in order to identify which features optimize classification evaluations and
555 decrease sequencing efforts. Using the DAT discovered by ANCOM, we iteratively removed the least
556 significant taxa from the input features (taxa) of the random forest classification models using the
557 backward elimination method.

558 We investigated external datasets from Spanish individuals (Iniesta et al., 2023) and Portuguese
559 individuals (Relvas et al., 2021) to confirm that our random forest classification was consistent. To
560 ascertain repeatability and dependability, the external datasets were processed using the same pipeline
561 and parameters as those used for our study participants.

562 **3.2.5 Data and code availability**

563 All sequences from the 250 study participants have been added to the Sequence Read Archives (project
564 ID PRJNA976179): <https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA976179>. Docker
565 image that employed throughout this study is available in the DockerHub: https://hub.docker.com/repository/docker/fumire/periodontitis_16s. Every code used in this study can be found on
566 GitHub: https://github.com/CompbioLabUnist/Periodontitis_16S.

568 **3.3 Results**

569 **3.3.1 Summary of clinical information and sequencing data**

570 Among clinical information of the study participants, clinical attachment level, probing depth, plaque
571 index, and gingival index, were significantly increased with periodontitis severity (Kruskal-Wallis test
572 $p < 0.001$), while sex were observed no significant difference (Table 2). Notably, clinical attachment level
573 and probing depth have significant differences among the periodontitis severities (MWU test $p < 0.01$;
574 Figure 15). Additionally, 71461.00 ± 11792.30 and 45909.78 ± 11404.65 reads per sample were obtained
575 before and after filtering low-quality reads and trimming extra-long tails, respectively (Figure 16).

576 **3.3.2 Diversity indices reveal differences among the periodontitis severities**

577 Rarefaction curves showed that the sequencing depth was sufficient (Figure 12). Alpha-diversity in-
578 dices indicated significant differences between the healthy and the periodontitis stages (MWU test
579 $p < 0.01$; Figure 7a-e); however, there were no significant differences between the periodontitis stages.
580 This emphasizes how essential it is to classify the salivary microbiome compositions and distinguish
581 between the stages of periodontitis using machine learning approaches.

582 The confidence ellipses of the tSNE-transformed beta-diversity index (Aitchison index) indicated
583 distinct distributions among the periodontitis severities (PERMANOVA $p \leq 0.001$; Figure 7f). Aitchison
584 index demonstrated significant differences every pairwise of the periodontitis severities (PERMANOVA
585 test $p \leq 0.001$; Table 7). Significant differences in the distances between periodontitis severities further
586 demonstrated the uniqueness of each severity of periodontitis (MWU test $p \leq 0.05$; Figure 7g-j).

587 **3.3.3 DAT among multiple periodontitis severities and their correlation**

588 Of the 425 total taxa that identified in the salivary microbiome composition (Figure 13), 20 DAT were
589 identified (Table 5). Three separate subgroups were formed from the participants-level abundances of the
590 DAT using a hierarchical clustering methodology (Figure 8a):

- 591 • Group 1
- 592 1. *Treponema* spp.
- 593 2. *Prevotella* sp. HMT 304
- 594 3. *Prevotella* sp. HMT 526
- 595 4. *Peptostreptococcaceae [XI][G-5]* saphenum
- 596 5. *Treponema* sp. HMT 260
- 597 6. *Mycoplasma faecium*
- 598 7. *Peptostreptococcaceae [XI][G-9]* brachy
- 599 8. *Lachnospiraceae [G-8] bacterium* HMT 500
- 600 9. *Peptostreptococcaceae [XI][G-6]* nodatum
- 601 10. *Fretibacterium* spp.

- 602 • Group 2
- 603 1. *Porphyromonas gingivalis*
- 604 2. *Campylobacter showae*
- 605 3. *Filifactor alocis*
- 606 4. *Treponema putidum*
- 607 5. *Tannerella forsythia*
- 608 6. *Prevotella intermedia*
- 609 7. *Porphyromonas* sp. HMT 285

- 610 • Group 3
- 611 1. *Actinomyces* spp.
- 612 2. *Corynebacterium durum*
- 613 3. *Actinomyces graevenitzii*

614 Ten DAT that were significant enriched in stage II and stage III, but deficient in healthy formed Group
 615 1. Furthermore, in comparison to the healthy, the seven DAT of Group 2 were significantly enriched in
 616 each of the stages of periodontitis. On the other hand, three DAT in Group 3 were deficient in stage II
 617 and stage III, but significantly enriched in healthy. The relative proportions of the DAT further supported
 618 these findings (Figure 8b), suggesting that the DAT is primarily linked to periodontitis rather than other
 619 salivary bacteria.

620 Correlation analysis from the DAT showed that DAT from Group 3 was negatively correlated with
 621 Group 1 and Group 2 (Figure 9), and strong correlations were observed the nine pairs of DAT (Figure 14).

622 3.3.4 Classification of periodontitis severities by random forest models

623 Based on the proportion of DAT, random forest classifier were trained to classify the periodontitis
 624 severities (Table 6). First of all, we conducted multi-label classification for the multiple periodontitis
 625 severities, namely healthy, stage I, stage II, and stage III. In this setting, we classified multiple periodontitis
 626 severities with the highest BA of 0.779 ± 0.029 (Table 4). AUC ranged between 0.81 and 0.94 (Figure
 627 10b).

628 Second, since timely detection in dentistry is demanding (Tonetti et al., 2018), we implemented a
 629 random forest classification for both healthy and stage I. Remarkably, the random forest classifier had
 630 the highest BA at 0.793 ± 0.123 (Table 4). In this setting, this model showed high AUC value for the
 631 classifying of stage I from healthy (AUC=0.85; Figure 10d).

632 Third, based on the findings that the salivary microbiome composition in stage II is more comparable
 633 to those in stage III than to other severities (Figure 7f and Figure 7j), we combined stage II and stage III
 634 to perform a multi-label classification.

Table 3: Clinical characteristics of the study subjects.

Significant differences were assessed using the Kruskal-Wallis test. NA: Not applicable.

| Index | Healthy | Stage I | Stage II | Stage III | p-value |
|-----------------------|-------------|-------------|-------------|-------------|----------|
| Age (year) | 33.83±13.04 | 43.30±14.28 | 50.26±11.94 | 51.08±11.13 | 6.18E-17 |
| Gender (Male) | 44 (44.0%) | 22 (44.0%) | 25 (50.0%) | 25 (50.0%) | NA |
| Smoking (Never) | 83 (83.0%) | 36 (72.0%) | 34 (68.0%) | 29 (58.0%) | NA |
| Smoking (Ex) | 12 (12.0%) | 7 (14.0%) | 9 (18.0%) | 10 (20.0%) | NA |
| Smoking (Current) | 2 (2.0%) | 7 (14.0%) | 7 (14.0%) | 10 (20.0%) | NA |
| Number of teeth | 28.03±2.23 | 27.36±1.80 | 26.72±2.89 | 25.74±4.34 | 8.07E-05 |
| Attachment level (mm) | 2.45±0.29 | 2.75±0.38 | 3.64±0.83 | 4.54±1.14 | 1.82E-35 |
| Probing depth (mm) | 2.42±0.29 | 2.61±0.40 | 3.27±0.76 | 3.95±0.88 | 6.43E-28 |
| Plaque index | 17.66±16.21 | 35.46±23.75 | 54.40±23.79 | 58.30±25.25 | 3.23E-22 |
| Gingival index | 0.09±0.16 | 0.44±0.46 | 0.85±0.52 | 1.06±0.52 | 2.59E-32 |

Table 4: Feature combinations and their evaluations

Classification performance with the most important taxon, the two most important taxa, and taxa with the best-balanced accuracy. *P.gingivalis* and *Act.* are *Porphyromonas gingivalis* and *Actinomyces* spp., respectively.

| Classification | Features | ACC | AUC | BA | F1 | PRE | SEN | SPE |
|--|--------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Healthy vs. Stage I vs. Stage II vs. Stage III | <i>P.gingivalis</i> | 0.758±0.051 | 0.716±0.177 | 0.677±0.068 | 0.839±0.034 | 0.839±0.034 | 0.516±0.102 | |
| | <i>P.gingivalis+Act.</i> | 0.792±0.043 | 0.822±0.105 | 0.723±0.057 | 0.861±0.029 | 0.861±0.029 | 0.584±0.086 | |
| | Top 5 taxa | 0.834±0.022 | 0.870±0.079 | 0.779±0.029 | 0.889±0.015 | 0.889±0.015 | 0.668±0.033 | |
| Healthy vs. Stage I | <i>Act.</i> | 0.687±0.116 | 0.725±0.145 | 0.647±0.159 | 0.762±0.092 | 0.760±0.128 | 0.781±0.116 | 0.513±0.224 |
| | <i>Act.+P.gingivalis</i> | 0.733±0.119 | 0.831±0.081 | 0.713±0.122 | 0.797±0.097 | 0.797±0.126 | 0.798±0.082 | 0.627±0.191 |
| | Top 9 taxa | 0.800±0.103 | 0.852±0.103 | 0.793±0.123 | 0.849±0.080 | 0.850±0.112 | 0.857±0.090 | 0.730±0.193 |
| Healthy vs. Stage I vs. Stages II/III | <i>P.gingivalis</i> | 0.776±0.042 | 0.736±0.196 | 0.748±0.047 | 0.832±0.031 | 0.832±0.031 | 0.664±0.062 | |
| | <i>P.gingivalis+Act.</i> | 0.843±0.035 | 0.876±0.109 | 0.823±0.039 | 0.882±0.026 | 0.882±0.026 | 0.764±0.052 | |
| | Top 6 taxa | 0.885±0.036 | 0.914±0.027 | 0.871±0.038 | 0.914±0.027 | 0.914±0.025 | 0.914±0.025 | 0.828±0.051 |
| Healthy vs. Stages I/II/III | <i>P.gingivalis</i> | 0.792±0.114 | 0.856±0.105 | 0.819±0.088 | 0.776±0.089 | 0.840±0.092 | 0.756±0.175 | 0.883±0.054 |
| | <i>P.gingivalis+Act.</i> | 0.828±0.121 | 0.926±0.074 | 0.847±0.116 | 0.797±0.123 | 0.800±0.126 | 0.830±0.191 | 0.864±0.074 |
| | Top 4 taxa | 0.860±0.078 | 0.953±0.049 | 0.885±0.066 | 0.832±0.079 | 0.840±0.128 | 0.864±0.157 | 0.905±0.070 |

Table 5: List of DAT among healthy status and periodontitis stages

| No. | Taxonomy | ANCOM W score |
|-----|---|---------------|
| 1 | <i>Porphyromonas gingivalis</i> | 424 |
| 2 | <i>Actinomyces</i> spp. | 424 |
| 3 | <i>Filifactor alocis</i> | 421 |
| 4 | <i>Prevotella intermedia</i> | 419 |
| 5 | <i>Treponema putidum</i> | 418 |
| 6 | <i>Tannerella forsythia</i> | 415 |
| 7 | <i>Porphyromonas</i> sp. HMT 285 | 412 |
| 8 | <i>Peptostreptococcaceae [XI][G-6] nodatum</i> | 412 |
| 9 | <i>Fretibacterium</i> spp. | 411 |
| 10 | <i>Mycoplasma faecium</i> | 411 |
| 11 | <i>Prevotella</i> sp. HMT 304 | 411 |
| 12 | <i>Lachnospiraceae [G-8] bacterium</i> HMT 500 | 409 |
| 13 | <i>Treponema</i> spp. | 408 |
| 14 | <i>Prevotella</i> sp. HMT 526 | 401 |
| 15 | <i>Peptostreptococcaceae [XI][G-9] brachy</i> | 400 |
| 16 | <i>Peptostreptococcaceae [XI][G-5] saphenum</i> | 398 |
| 17 | <i>Campylobacter showae</i> | 395 |
| 18 | <i>Treponema</i> sp. HMT 260 | 393 |
| 19 | <i>Corynebacterium durum</i> | 393 |
| 20 | <i>Actinomyces graevenitzii</i> | 387 |

Table 6: Feature the importance of taxa in the classification of different periodontal statuses
 Taxa are ranked in descending order of importance; from most important to least important.

| Condition | Healthy vs. Stage I vs. Stage II vs. Stage III | | | Healthy vs. Stage I | | | Healthy vs. Stage I vs. Stage II/III | | | Healthy vs. Stage III/IV | | |
|-----------|--|-------|--|---------------------|--|-------|--|-------|---|--------------------------|------------|--|
| | Rank | Taxa | Importance | Taxa | Importance | Taxa | Importance | Taxa | Importance | Taxa | Importance | |
| 1 | <i>Porphyromonas gingivalis</i> | 0.297 | <i>Actinomyces spp.</i> | 0.195 | <i>Porphyromonas gingivalis</i> | 0.360 | <i>Porphyromonas gingivalis</i> | 0.426 | <i>Porphyromonas gingivalis</i> | 0.461 | | |
| 2 | <i>Actinomyces spp.</i> | 0.195 | <i>Actinomyces graevenitzii</i> | 0.054 | <i>Actinomyces spp.</i> | 0.125 | <i>Actinomyces spp.</i> | 0.244 | <i>Actinomyces spp.</i> | 0.257 | | |
| 3 | <i>Prevotella intermedia</i> | 0.054 | <i>Actinomyces graevenitzii</i> | 0.052 | <i>Porphyromonas sp. HMT 285</i> | 0.055 | <i>Actinomyces graevenitzii</i> | 0.049 | <i>Actinomyces spp.</i> | 0.059 | | |
| 4 | <i>Actinomyces graevenitzii</i> | 0.052 | <i>Lachnospiraceae (G-8) bacterium HMT 500</i> | 0.050 | <i>Lachnospiraceae (G-8) bacterium HMT 500</i> | 0.052 | <i>Corynebacterium durum</i> | 0.046 | <i>Corynebacterium durum</i> | 0.035 | | |
| 5 | <i>Filifactor alocis</i> | 0.050 | <i>Campylobacter showae</i> | 0.042 | <i>Campylobacter showae</i> | 0.050 | <i>Prevotella intermedia</i> | 0.036 | <i>Filifactor alocis</i> | 0.032 | | |
| 6 | <i>Campylobacter showae</i> | 0.042 | <i>Filifactor alocis</i> | 0.040 | <i>Corynebacterium durum</i> | 0.052 | <i>Tannerella forsythia</i> | 0.039 | <i>Campylobacter showae</i> | 0.023 | | |
| 7 | <i>Porphyromonas sp. HMT 285</i> | 0.040 | <i>Treponema spp.</i> | 0.032 | <i>Treponema spp.</i> | 0.037 | <i>Porphyromonas sp. HMT 285</i> | 0.029 | <i>Prevotella spp.</i> | 0.023 | | |
| 8 | <i>Corynebacterium durum</i> | 0.032 | <i>Tannerella forsythia</i> | 0.026 | <i>Tannerella forsythia</i> | 0.026 | <i>Peptostreptococcaceae (XII)(G-9) brachy</i> | 0.025 | <i>Prevotella intermedia</i> | 0.022 | | |
| 9 | <i>Treponema spp.</i> | 0.032 | <i>Prevotella spp.</i> | 0.025 | <i>Prevotella spp.</i> | 0.026 | <i>Peptostreptococcaceae (XII)(G-9) brachy</i> | 0.025 | <i>Tannerella forsythia</i> | 0.022 | | |
| 10 | <i>Tannerella forsythia</i> | 0.026 | <i>Freibacterium spp.</i> | 0.023 | <i>Freibacterium spp.</i> | 0.023 | <i>Peptostreptococcaceae (XII)(G-9) brachy</i> | 0.025 | <i>Treponema spp.</i> | 0.022 | | |
| 11 | <i>Treponema spp.</i> | 0.025 | <i>Peptostreptococcaceae (XII)(G-9) brachy</i> | 0.021 | <i>Peptostreptococcaceae (XII)(G-9) brachy</i> | 0.018 | <i>Lachnospiraceae (G-8) bacterium HMT 500</i> | 0.018 | <i>Peptostreptococcaceae (XII)(G-9) brachy</i> | 0.015 | | |
| 12 | <i>Freibacterium spp.</i> | 0.023 | <i>Peptostreptococcaceae (XII)(G-9) brachy</i> | 0.019 | <i>Peptostreptococcaceae (XII)(G-9) brachy</i> | 0.018 | <i>Peptostreptococcaceae (XII)(G-6) nodatum</i> | 0.011 | <i>Peptostreptococcaceae (XII)(G-6) nodatum</i> | 0.010 | | |
| 13 | <i>Peptostreptococcaceae (XII)(G-9) brachy</i> | 0.021 | <i>Peptostreptococcaceae (XII)(G-9) brachy</i> | 0.019 | <i>Peptostreptococcaceae (XII)(G-9) brachy</i> | 0.014 | <i>Treponema putidum</i> | 0.009 | <i>Peptostreptococcaceae (XII)(G-6) nodatum</i> | 0.009 | | |
| 14 | <i>Treponema sp. HMT 260</i> | 0.019 | <i>Prevotella sp. HMT 526</i> | 0.018 | <i>Prevotella sp. HMT 526</i> | 0.011 | <i>Prevotella sp. HMT 526</i> | 0.008 | <i>Peptostreptococcaceae (XII)(G-6) nodatum</i> | 0.008 | | |
| 15 | <i>Prevotella sp. HMT 526</i> | 0.018 | <i>Prevotella sp. HMT 260</i> | 0.018 | <i>Prevotella sp. HMT 260</i> | 0.008 | <i>Freibacterium spp.</i> | 0.011 | <i>Peptostreptococcaceae (XII)(G-6) nodatum</i> | 0.008 | | |
| 16 | <i>Peptostreptococcaceae (XII)(G-6) nodatum</i> | 0.018 | <i>Prevotella sp. HMT 304</i> | 0.017 | <i>Peptostreptococcaceae (XII)(G-6) nodatum</i> | 0.008 | <i>Treponema sp. HMT 260</i> | 0.005 | <i>Freibacterium spp.</i> | 0.004 | | |
| 17 | <i>Prevotella sp. HMT 304</i> | 0.017 | <i>Mycoplasma faecium</i> | 0.014 | <i>Mycoplasma faecium</i> | 0.004 | <i>Prevotella sp. HMT 304</i> | 0.005 | <i>Mycoplasma faecium</i> | 0.004 | | |
| 18 | <i>Mycoplasma faecium</i> | 0.014 | <i>Prevotella sp. HMT 304</i> | 0.014 | <i>Prevotella sp. HMT 304</i> | 0.003 | <i>Mycoplasma faecium</i> | 0.005 | <i>Prevotella sp. HMT 304</i> | 0.003 | | |
| 19 | <i>Peptostreptococcaceae (XII)(G-5) saphenum</i> | 0.013 | <i>Lachnospiraceae (G-8) bacterium HMT 500</i> | 0.013 | <i>Peptostreptococcaceae (XII)(G-5) saphenum</i> | 0.003 | <i>Peptostreptococcaceae (XII)(G-5) saphenum</i> | 0.004 | <i>Prevotella sp. HMT 304</i> | 0.004 | | |
| 20 | <i>Lachnospiraceae (G-8) bacterium HMT 500</i> | 0.013 | | | | | | | | | | |

Table 7: Beta-diversity pairwise comparisons on the periodontitis statuses

Statistically significant (p-value) was determined by the PERMANOVA test.

| Group 1 | Group 2 | p-value |
|----------------|----------------|----------------|
| Healthy | Stage I | 0.001 |
| Healthy | Stage II | 0.001 |
| Healthy | Stage III | 0.001 |
| Stage I | Stage II | 0.001 |
| Stage I | Stage III | 0.001 |
| Stage II | Stage III | 0.737 |




Figure 7: **Diversity indices.**

Alpha-diversity indices (a-e) indicate that healthy controls have increased heterogeneity than periodontitis stages as measured by: (a) ace (b) chao1 (c) Fisher alpha (d) Margalef, and (e) observed ASVs. (f) The beta-diversity index (weighted UniFrac) was visualized using a tSNE-transformed plot. The confidence ellipses are shown to display the distribution of each periodontitis stage. The distance to each stage demonstrated that each periodontitis stage was distinguished from the other periodontitis stages: (g) distance to Healthy (h) distance to Stage I (i) distance to Stage II, and (j) distance to Stage III. Statistical significance determined by the MWU test and the PERMANOVA test: $p \leq 0.01$ (**) and $p \leq 0.0001$ (****).




Figure 8: **Differentially abundant taxa (DAT).**

DAT that were identified by ANCOM. **(a)** Heatmap of clustered DAT with similar distribution among subjects. Group 1, Group 2, and Group 3 are marked in red, black, and green, respectively. **(b)** Box plots showing the proportions of DAT. Taxa were sorted by their importance according to ANCOM.




Figure 9: Correlation heatmap.

Pearson's correlations between DAT in healthy status and periodontitis stages. Statistical significance was determined by strong correlation, i.e., $| \text{coefficient} | \geq 0.5$ (*).




Figure 10: Random forest classification metrics.

The classification metrics in the random forest classifications were as follows: ACC, AUC, BA, F1, PRE, SEN, and SPE. **(a)** Classification performance for healthy vs. stage I vs. stage II vs. stage III. **(b)** ROC curve for the highest BA of (a). **(c)** Classification performance for healthy vs. stage I. **(d)** ROC curve on the highest BA of (c). **(e)** Classification performance for healthy vs. stage I vs. stages II/III. **(f)** ROC curve for the highest BA of (e). **(g)** Classification performance for healthy vs. stages I/II/III. **(h)** ROC curve for the highest BA of (h).




Figure 11: **Random forest classification metrics from external datasets.**

The classification metrics in the random forest classifications were as follows: ACC, AUC, BA, F1, PRE, SEN, and SPE. **(a)** Classification performance for healthy vs. stage I vs. stage II vs. stage III. **(b)** Classification performance for healthy vs. stage I. **(c)** Classification performance for healthy vs. stage I vs. stages II/III. **(d)** Classification performance for healthy vs. stages I/II/III.




Figure 12: **Rarefaction curves for alpha-diversity indices.**

Rarefaction of (a) chao1 (b) margalef, and (c) observed ASVs were generated to measure species richness and determine the sampling depth of each sample.




Figure 13: Salivary microbiome compositions in the different periodontal statuses.

Stacked bar plot of the absolute abundance of bacterial species for all samples (**a**) and the mean absolute abundance of bacterial species in the healthy, stage I, stage II, and stage III groups (**b**).




Figure 14: Correlation plots for differentially abundant taxa.

We selected the combinations of DAT with absolute Spearman correlation coefficients greater than 0.5. The color represents periodontal healthy periodontal statuses (green: healthy, cyan: stage I, yellow: stage II, and red: stage III).




Figure 15: **Clinical measurements by the periodontitis statuses.**

Comparisons of clinical measurement among healthy controls and patients with various periodontitis stages. **(a)** Clinical attachment level **(b)** Probing depth. Statistical significance determined by the MWU test: $p \leq 0.01$ (**) and $p \leq 0.0001$ (****).




Figure 16: **Number of read counts by the periodontitis statuses.**

Comparisons of the number of read counts among healthy controls and patients with various periodontitis stages. **(a)** Before quality check **(b)** After quality check. Statistical significance determined by the MWU test: $p > 0.05$ (ns), $p \leq 0.001$ (***) , and $p \leq 0.0001$ (****).




Figure 17: Proportion of DAT.

(a) *Actinomyces graevenitzii* (b) *Actinomyces* spp. (c) *Campylobacter showae* (d) *Corynebacterium durum* (e) *Filifactor alocis* (f) *Fretibacterium* spp. (g) *Lachnospiraceae [G-8] bacterium HMT 500* (h) *Mycoplasma faecium* (i) *Peptostreptococcaceae [XI][G-5] saphenum* (j) *Peptostreptococcaceae [XI][G-6] nodatum* (k) *Peptostreptococcaceae [XI][G-9] brachy* (l) *Porphyromonas gingivalis* (m) *Porphyromonas* sp. HMT 285 (n) *Prevotella intermedia* (o) *Prevotella* sp. HMT 304 (p) *Prevotella* sp. HMT 526 (q) *Tannerella forsythia* (r) *Treponema putidum* (s) *Treponema* sp. HMT 260 (t) *Treponema* spp. Statistical significance determined by the MWU test: $p > 0.05$ (ns), $p \leq 0.05$ (*), $p \leq 0.01$ (**), $p \leq 0.001$ (***), and $p \leq 0.0001$ (****).




Figure 18: Random forest classification metrics with the full microbiome compositions and ANCOM-selected DAT compositions.

The classification metrics in the random forest classifications were as follows: ACC, AUC, BA, F1, PRE, SEN, and SPE. **(a)** Classification performance for healthy vs. stage I vs. stage II vs. stage III. **(b)** ROC curve for the highest BA of (a). **(c)** Classification performance for healthy vs. stage I. **(d)** ROC curve on the highest BA of (c). **(e)** Classification performance for healthy vs. stage I vs. stages II/III. **(f)** ROC curve for the highest BA of (e). **(g)** Classification performance for healthy vs. stages I/II/III. **(h)** ROC curve for the highest BA of (g). Statistical significance determined by the MWU test: $p > 0.05$ (ns), $p \leq 0.01$ (**), and $p \leq 0.0001$ (****).




Figure 19: **Alpha-diversity indices account for evenness.**

Alpha-diversity indices (**a-d**) indicate that the heterogeneity between the periodontitis stages as measured by: **(a)** Berger-Parker *d* **(b)** Gini **(c)** Shannon **(d)** Simpson. Statistical significance determined by the MWU test: $p \leq 0.05$ (*) and $p \leq 0.01$ (**)




Figure 20: Gradient Boosting classification metrics.

The classification metrics in the random forest classifications were as follows: ACC, AUC, BA, F1, PRE, SEN, and SPE. The feature counts mean that the classification model trained on the most important n features as the Table 5. **(a)** Comparison of Random forest (RF) and Gradient boosting (GB) for healthy vs. stage I vs. stage II vs. stage III. **(b)** Comparison of RF and GB for the highest BA of (a). **(c)** Classification performance for healthy vs. stage I. **(d)** Comparison of RF and GB for healthy vs. stage I vs. stages II/III. **(e)** Comparison of RF and GB for the highest BA of (d). **(f)** Comparison of RF and GB for Healthy vs. Stage I vs. Stages II/III. **(g)** Classification performance for healthy vs. stages I/II/III. **(h)** Comparison of RF and GB for Healthy vs. Stages I/II/III.

635 **3.4 Discussion**

636 In order to investigate at potential alterations in the salivary microbiome compositions based on periodontal
637 statuses, including healthy, stage I, stage II, and stage III, we employed 16S rRNA gene sequencing to
638 perform a cross-sectional periodontitis analysis. In this study, the 2018 periodontitis classification served
639 as the basis for the classification of periodontitis severities (Papapanou et al., 2018). There were notable
640 variations in the salivary microbiome composition among the multiple severities of periodontitis (Figure
641 13). Furthermore, our random forest classification model based on the proportions of DAT in the salivary
642 microbiome compositions across study participants to predict multiple periodontitis statuses with high
643 AUC of 0.870 ± 0.079 (Table 4).

644 Previous research identified the red complex as the primary pathogens of periodontitis (Listgarten,
645 1986): *Porphyromonas gingivalis*, *Tannerella forsythia*, and *Treponema denticola*. Other studies, however,
646 have shown that periodontal pathogens communicate with other bacteria in the salivary microbiome
647 networks to generate dental plaque prior to the pathogenesis and development of periodontitis (Lamont &
648 Jenkinson, 2000; Rosan & Lamont, 2000; Yoshimura, Murakami, Nishikawa, Hasegawa, & Kawaminami,
649 2009).

650 Using subgingival plaque collections, recent researches have suggested a connection between the
651 periodontitis severity and the salivary microbiome compositions (Altabtbaei et al., 2021; Iniesta et al.,
652 2023; Nemoto et al., 2021). Therefore, we have examined the salivary microbiome compositions of
653 patients with multiple severities of periodontitis and periodontally healthy controls, extending on earlier
654 studies.

655 According to our findings, the salivary microbiome compositions have 425 taxa (Figure 13). We
656 computed the alpha-diversity indices to determine the variability within each salivary microbiome
657 composition, including ace (Chao & Lee, 1992), chao1 (Chao, 1984), fisher alpha (Fisher et al., 1943),
658 margalef (Magurran, 2021), observed ASVs (DeSantis et al., 2006), Berger-Parker *d* (Berger & Parker,
659 1970), Gini index (Gini, 1912), Shannon (Weaver, 1963), and Simpson (Simpson, 1949) (Figure 7 and
660 Figure 19). Alpha-diversity indices suggested that the microbial richness of periodontally healthy controls
661 was higher than that of patients with periodontitis (Figure 7a-e and Figure 19). These results are in line with
662 findings with that patients with advanced periodontitis, namely stage II and stage III, have less diversified
663 communities than periodontally healthy controls (Jorth et al., 2014). Recognizing that the periodontitis
664 severity increases the amount of *Porphyromonas gingivalis*, the salivary microbiome compositions from
665 periodontally healthy controls conserved microbial networks dominated by *Streptococcus* spp. (Figure
666 13). *Porphyromonas gingivalis* is one of the known periodontal pathogen that could cause dysbiosys
667 in the salivary microbiomes, suggesting in the pathophysiology of periodontitis. Despite this finding,
668 earlier research found that subgingival microbiome of patients with periodontitis had a greater alpha-
669 diversity index (observed ASVs) than that of healthy controls (Iniesta et al., 2023), might due to the
670 different sampling sites between saliva and subgingival plaque. On the other hand, another research
671 has addressed significant discrepancies in alpha-diversity indices from subgingival plaque, saliva, and
672 tongue biofilms from healthy controls and periodontitis patients, resulting the highest alpha-diversity

index in saliva collections (Belstrøm et al., 2021). Moreover, early-stage periodontitis, namely stage I, did not determine statistically significant differences in alpha-diversity indices compared to advanced periodontitis, including stage II and stage III (Figure 7a-e). Accordingly, saliva collection of stage I periodontitis may exhibit heterogeneity, indicating a midpoint condition between a healthy state and advanced periodontitis (stage II and stage III). Likewise, gingivitis is often associated with low abundances of the majority of periodontal pathogens, including *Porphyromonas gingivalis*, *Tannerella forsythia*, and *Treponema denticola* (Abusleme et al., 2021). Compared to healthy controls, patients with stage I periodontitis have higher detection rates of *Porphyromonas gingivalis* and *Tannerella forsythia* (Tanner et al., 2006, 2007).

Therefore, we calculated beta-diversity indices to analyze the differences between the study participants. The distances for the multiple stages of periodontitis, including stage I, stage II, and stage III, as well as healthy controls (Figure 4g-j and Table 7), suggesting notable differences among the multiple periodontitis severities. In other words, the composition of the salivary microbiome compositions varies depending on the periodontitis stages, so that supporting the findings from a previous study (Iniesta et al., 2023). Taken together that it is nearly impossible to fully restore the attachment level after it has been lost due to the progression and development of periodontitis, the ability to rapidly screen for periodontitis in its early phases using saliva collections would be highly beneficial for effective disease management and treatment.

Of the total of 425 taxa in the salivary microbiome composition that have been identified (Figure 13), ANCOM was applied to select 20 taxa as the DAT that indicated notable abundance variation among the periodontitis severities (Figure 8 and Table 5). Three sub-groups were formed from the DAT using hierarchical clustering (Figure 8a). Surprisingly, two of the red complex pathogens (Rôças, Siqueira Jr, Santos, Coelho, & de Janeiro, 2001), *Porphyromonas gingivalis* and *Tannerella forsythia*, were classified in Group 2 and were more prevalent in stage II and stage III periodontitis compared to healthy controls. *Campylobacter showae* was additionally placed in Group 2 of the orange complex pathogens (Gambin et al., 2021). Furthermore, some of the DAT in Group 2 have reported their crucial roles in pathogenesis and development of periodontitis: *Filifactor alocis* (Aruni et al., 2015), *Treponema putidum* (Wyss et al., 2004), *Tannerella forsythia* (Stafford, Roy, Honma, & Sharma, 2012; W. Zhu & Lee, 2016), and *Prevotella intermedia* (Karched, Bhardwaj, Qudeimat, Al-Khabbaz, & Ellepol, 2022). Taken together, this indicates that DAT in Group 2 is essential to periodontitis. The portion of some Group 1 DAT, including *Peptostreptococcaceae[XI][G-5] saphenum*, *Peptostreptococcaceae[XI][G-6] nodatum*, and *Peptostreptococcaceae[XI][G-9] brachy*, in healthy controls and patients with periodontitis significantly differed, according to earlier research (Lafaurie et al., 2022). These outcomes support our research, implying that Group 1 DAT are also essential to the etiology and progression of periodontitis. However, in contrast to patients with periodontitis, Group 3 DAT, namely *Corynebacterium durum* and *Actinomyces graevenitzii*, were enriched in healthy controls, which is consistent with earlier research (Redanz et al., 2021; Nibali et al., 2020).

In our correlation analysis (Figure 9), we have discovered strongly negative correlations (coefficient ≤ -0.5) between DAT of Group 3 and these of Group 1 and Group 2; we have also identified nine DAT

pairs with strong correlations (coefficient $\leq -0.5 \vee$ coefficient ≥ 0.5) (Figure 14). Interestingly, there were strongly negative correlations (coefficient ≤ -0.5) between Group 2 DAT and *Actinomyces* spp., taxa which belong to Group 3: *Filifactor alocis* (Figure 14a), *Porphyromonas gingivalis* (Figure 14b), and *Treponema putidum* (Figure 14c). Taken together that pathogens, including *Filifactor alocis* (Aja, Mangar, Fletcher, & Mishra, 2021; Hiranmayi, Sirisha, Rao, & Sudhakar, 2017), *Porphyromonas gingivalis* (Rôças et al., 2001), and *Treponema putidum* (Wyss et al., 2004), become dominant taxa in patients with stage III periodontitis. On the other hand, commensal salivary bacteria, such as *Actinomyces* spp., gradually declined. Additionally, several DAT from Group 1 and Group 2 exhibited strong positive correlations (coefficient ≥ 0.5) (Figure 14d-i). It has been established that all of these DAT from Group 1 and Group 2 are periodontal pathogens: *Filifactor alocis* (Aja et al., 2021; Hiranmayi et al., 2017), *Fretibacterium* spp. (Teles, Wang, Hajishengallis, Hasturk, & Marchesan, 2021), *Lachnospiraceae[G-8] bacterium HMT 500* (Lafaurie et al., 2022), *Peptostreptococcaceae[XI][G-6] nodatum* (Lafaurie et al., 2022; Haffajee, Teles, & Socransky, 2006), *Peptostreptococcaceae[XI][G-9] brachy* (Lafaurie et al., 2022), and *Treponema putidum* (Wyss et al., 2004). Thus, these fundamental roles of identified periodontal pathogens in the pathophysiology and progression of periodontitis are further supported by these strong positive correlations (coefficient ≥ 0.5), suggesting that advanced periodontitis, i.e., stage III, might arise from the additional DAT from Group 1 and Group 2.

Moreover, to predict periodontitis statuses from salivary microbiome composition, we have constructed machine-learning classification models based on random forest for four classification settings:

1. healthy vs. stage I vs. stage II vs. stage III
2. healthy vs. stage I
3. healthy vs. stage I vs. stages II/III
4. healthy vs. stages I/II/III

Porphyromonas gingivalis and *Actinomyces* spp. were the two most important taxa (feature) in all classification settings. This finding aligns with a recent study that identifies *Actinomyces* spp. as the most prevalent bacteria in both the healthy gingivitis controls, while *Porphyromonas gingivalis* is recognized as the most predominant taxon within the periodontitis subjects, based on analyses of subgingival plaque samples (Nemoto et al., 2021). We have previously developed machine learning models for the classification of periodontitis, with the objective of predicting the severities of chronic periodontitis by analyzing the copy numbers of nine known salivary bacteria species. We classified healthy controls and patients with periodontitis utilizing bacterial combinations in conjunction with a random forest model (E.-H. Kim et al., 2020):

- AUC: 94%
- BA: 84%
- SEN: 95%
- SPE: 72%

Another study established a machine-learning model for the classification of periodontitis, employing 266 species derived from the buccal microbiome (Na et al., 2020):

- AUC: 92%

751 • BA: 84%

752 • SEN: 94%

753 • SPE: 74%

754 By separating patients with periodontitis from healthy controls using only four DAT, *e.g.* *Actinomyces*
755 *graevenitzii*, *Actinomyces* spp., *Corynebacterium durum*, and *Porphyromonas gingivalis*, our machine
756 learning model performed better than previously published models (Figure 10, Table 4, and Table 6):

757 • AUC: $95.3\% \pm 4.9\%$

758 • BA: $88.5\% \pm 6.6\%$

759 • SEN: $86.4\% \pm 15.7\%$

760 • SPE: $90.5\% \pm 7.0\%$

761 This result showed that by detecting Group 3 bacteria that were substantially abundant in health
762 controls than patients with periodontitis, our study increased BA by at least 5% and SPE by at least 17%.

763 Furthermore, we have validated our machine-learning prediction model using openly accessible 16S
764 gene rRNA sequencing data from Portuguese (Iniesta et al., 2023) and Spanish participants (Relvas et
765 al., 2021) in order to ensure the consistency of our random forest classification model (Figure 11). Our
766 classification models employed in this study were primarily developed and assessed on Korean study par-
767 ticipants, which may limit their generalizability to other ethnic groups with different salivary microbiome
768 compositions (Premaraj et al., 2020; Renson et al., 2019). Therefore, the evaluations of this periodonti-
769 tis classification models can be affected by ethnic-specific variances and differences, highlighting the
770 necessity for additional validation and adjustment across a spectrum of ethnic backgrounds.

771 Regarding the clinical characteristics and potential confounders influencing the analysis of salivary
772 microbiome compositions connected with periodontitis severity, this study had a number of limitations
773 that were pointed out. We did not offer clinical information, such as the percentage of teeth, the percentage
774 of bleeding on probing, nor dental furcation involvement, even though we did gather information on
775 attachment level, probing depth, plaque index, and gingival index; this might have it challenging to present
776 thorough and in-depth data about periodontal health. Moreover, the broad age range may make it tougher
777 to evaluate the relationship between age and periodontitis statuses, providing the necessity for future
778 studies to consider into account more comprehensive clinical characteristics associated with periodontitis.
779 Additionally, potential confounders—*e.g.* body mass index and e-cigarette use—which might have affected
780 dental health and salivary microbiome composition were disregarding consideration in addition to smoking
781 status and systemic diseases. Thus, future research incorporating these components would offer a more
782 thorough knowledge of how lifestyle factors interact and affect the salivary microbiome composition and
783 periodontal health. Throughout, resolving these limitations will advance our understanding in pathogenesis
784 and development of periodontitis, offering significant novel insights on the causal connection between
785 systemic diseases and the salivary microbiome compositions.

786 **4 Colon microbiome**

787 **4.1 Introduction**

788 **4.2 Materials and methods**

789 **4.3 Results**

790 **4.4 Discussion**

⁷⁹¹ **5 Conclusion**

⁷⁹² In conclusion, the research described in this doctoral dissertation was conducted to identify significant ...

⁷⁹³ In the section 2, I show that

794 References

- 795 Aagaard, K., Ma, J., Antony, K. M., Ganu, R., Petrosino, J., & Versalovic, J. (2014). The placenta harbors
796 a unique microbiome. *Science translational medicine*, 6(237), 237ra65–237ra65.
- 797 Abusleme, L., Hoare, A., Hong, B.-Y., & Diaz, P. I. (2021). Microbial signatures of health, gingivitis,
798 and periodontitis. *Periodontology 2000*, 86(1), 57–78.
- 799 Aitchison, J., Barceló-Vidal, C., Martín-Fernández, J. A., & Pawlowsky-Glahn, V. (2000). Logratio
800 analysis and compositional distance. *Mathematical geology*, 32, 271–275.
- 801 Aja, E., Mangar, M., Fletcher, H., & Mishra, A. (2021). Filifactor alocis: recent insights and advances.
802 *Journal of dental research*, 100(8), 790–797.
- 803 Alelyani, S. (2021). Stable bagging feature selection on medical data. *Journal of Big Data*, 8(1), 11.
- 804 Altabtbaei, K., Maney, P., Ganesan, S. M., Dabdoub, S. M., Nagaraja, H. N., & Kumar, P. S. (2021). Anna
805 karenina and the subgingival microbiome associated with periodontitis. *Microbiome*, 9, 1–15.
- 806 Altingöz, S. M., Kurgan, Ş., Önder, C., Serdar, M. A., Ünlütürk, U., Uyanık, M., ... Günhan, M.
807 (2021). Salivary and serum oxidative stress biomarkers and advanced glycation end products in
808 periodontitis patients with or without diabetes: A cross-sectional study. *Journal of periodontology*,
809 92(9), 1274–1285.
- 810 Alverdy, J., Hyoju, S., Weigerinck, M., & Gilbert, J. (2017). The gut microbiome and the mechanism of
811 surgical infection. *Journal of British Surgery*, 104(2), e14–e23.
- 812 Anderson, M. J. (2014). Permutational multivariate analysis of variance (permanova). *Wiley statsref:
813 statistics reference online*, 1–15.
- 814 Aruni, A. W., Mishra, A., Dou, Y., Chioma, O., Hamilton, B. N., & Fletcher, H. M. (2015). Filifactor
815 alocis—a new emerging periodontal pathogen. *Microbes and infection*, 17(7), 517–530.
- 816 Barlow, G. M., Yu, A., & Mathur, R. (2015). Role of the gut microbiome in obesity and diabetes mellitus.
817 *Nutrition in clinical practice*, 30(6), 787–797.
- 818 Basavaprabhu, H., Sonu, K., & Prabha, R. (2020). Mechanistic insights into the action of probiotics
819 against bacterial vaginosis and its mediated preterm birth: An overview. *Microbial pathogenesis*,
820 141, 104029.
- 821 Belstrøm, D., Constancias, F., Drautz-Moses, D. I., Schuster, S. C., Veleba, M., Mahé, F., & Givskov, M.
822 (2021). Periodontitis associates with species-specific gene expression of the oral microbiota. *npj
823 Biofilms and Microbiomes*, 7(1), 76.
- 824 Berger, W. H., & Parker, F. L. (1970). Diversity of planktonic foraminifera in deep-sea sediments.

- 825 *Science*, 168(3937), 1345–1347.
- 826 Berghella, V. (2012). Universal cervical length screening for prediction and prevention of preterm birth.
827 *Obstetrical & gynecological survey*, 67(10), 653–657.
- 828 Blencowe, H., Cousens, S., Oestergaard, M. Z., Chou, D., Moller, A.-B., Narwal, R., ... others (2012).
829 National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends
830 since 1990 for selected countries: a systematic analysis and implications. *The lancet*, 379(9832),
831 2162–2172.
- 832 Bolstad, A., Jensen, H. B., & Bakken, V. (1996). Taxonomy, biology, and periodontal aspects of
833 *fusobacterium nucleatum*. *Clinical microbiology reviews*, 9(1), 55–71.
- 834 Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., ... others
835 (2019). Reproducible, interactive, scalable and extensible microbiome data science using qiime 2.
836 *Nature biotechnology*, 37(8), 852–857.
- 837 Breiman, L. (2001). Random forests. *Machine learning*, 45, 5–32.
- 838 Brennan, C. A., & Garrett, W. S. (2019). *Fusobacterium nucleatum*—symbiont, opportunist and
839 *oncobacterium*. *Nature Reviews Microbiology*, 17(3), 156–166.
- 840 Bryll, R., Gutierrez-Osuna, R., & Quek, F. (2003). Attribute bagging: improving accuracy of classifier
841 ensembles by using random feature subsets. *Pattern recognition*, 36(6), 1291–1302.
- 842 Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016).
843 Dada2: High-resolution sample inference from illumina amplicon data. *Nature methods*, 13(7),
844 581–583.
- 845 Canakci, V., & Canakci, C. F. (2007). Pain levels in patients during periodontal probing and mechanical
846 non-surgical therapy. *Clinical oral investigations*, 11, 377–383.
- 847 Castaner, O., Goday, A., Park, Y.-M., Lee, S.-H., Magkos, F., Shiow, S.-A. T. E., & Schröder, H. (2018).
848 The gut microbiome profile in obesity: a systematic review. *International journal of endocrinology*,
849 2018(1), 4095789.
- 850 Champagne, C., McNairn, H., Daneshfar, B., & Shang, J. (2014). A bootstrap method for assessing
851 classification accuracy and confidence for agricultural land use mapping in canada. *International
852 Journal of Applied Earth Observation and Geoinformation*, 29, 44–52.
- 853 Chao, A. (1984). Nonparametric estimation of the number of classes in a population. *Scandinavian
854 Journal of statistics*, 265–270.
- 855 Chao, A., & Lee, S.-M. (1992). Estimating the number of classes via sample coverage. *Journal of the
856 American statistical Association*, 87(417), 210–217.
- 857 Chapple, I. L., Mealey, B. L., Van Dyke, T. E., Bartold, P. M., Dommisch, H., Eickholz, P., ... others
858 (2018). Periodontal health and gingival diseases and conditions on an intact and a reduced
859 periodontium: Consensus report of workgroup 1 of the 2017 world workshop on the classification
860 of periodontal and peri-implant diseases and conditions. *Journal of periodontology*, 89, S74–S84.
- 861 Chen, T., Marsh, P., & Al-Hebshi, N. (2022). Smdi: an index for measuring subgingival microbial
862 dysbiosis. *Journal of dental research*, 101(3), 331–338.
- 863 Chen, T., Yu, W.-H., Izard, J., Baranova, O. V., Lakshmanan, A., & Dewhirst, F. E. (2010). The human

- oral microbiome database: a web accessible resource for investigating oral microbe taxonomic and genomic information. *Database*, 2010.
- Chen, X., D’Souza, R., & Hong, S.-T. (2013). The role of gut microbiota in the gut-brain axis: current challenges and perspectives. *Protein & cell*, 4, 403–414.
- Chew, R. J. J., Tan, K. S., Chen, T., Al-Hebshi, N. N., & Goh, C. E. (2024). Quantifying periodontitis-associated oral dysbiosis in tongue and saliva microbiomes—an integrated data analysis. *Journal of Periodontology*.
- Čižmárová, B., Tomečková, V., Hubková, B., Hurajtová, A., Ohlasová, J., & Birková, A. (2022). Salivary redox homeostasis in human health and disease. *International Journal of Molecular Sciences*, 23(17), 10076.
- Cullin, N., Antunes, C. A., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021). Microbiome and cancer. *Cancer Cell*, 39(10), 1317–1341.
- DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., … Andersen, G. L. (2006). Greengenes, a chimera-checked 16s rrna gene database and workbench compatible with arb. *Applied and environmental microbiology*, 72(7), 5069–5072.
- Doyle, R., Alber, D., Jones, H., Harris, K., Fitzgerald, F., Peebles, D., & Klein, N. (2014). Term and preterm labour are associated with distinct microbial community structures in placental membranes which are independent of mode of delivery. *Placenta*, 35(12), 1099–1101.
- Faith, D. P. (1992). Conservation evaluation and phylogenetic diversity. *Biological conservation*, 61(1), 1–10.
- Fettweis, J. M., Serrano, M. G., Brooks, J. P., Edwards, D. J., Girerd, P. H., Parikh, H. I., … others (2019). The vaginal microbiome and preterm birth. *Nature medicine*, 25(6), 1012–1021.
- Fisher, R. A., Corbet, A. S., & Williams, C. B. (1943). The relation between the number of species and the number of individuals in a random sample of an animal population. *The Journal of Animal Ecology*, 42–58.
- Francescone, R., Hou, V., & Grivennikov, S. I. (2014). Microbiome, inflammation, and cancer. *The Cancer Journal*, 20(3), 181–189.
- Gambin, D. J., Vitali, F. C., De Carli, J. P., Mazzon, R. R., Gomes, B. P., Duque, T. M., & Trentin, M. S. (2021). Prevalence of red and orange microbial complexes in endodontic-periodontal lesions: a systematic review and meta-analysis. *Clinical Oral Investigations*, 1–14.
- Gilbert, J. A., Blaser, M. J., Caporaso, J. G., Jansson, J. K., Lynch, S. V., & Knight, R. (2018). Current understanding of the human microbiome. *Nature medicine*, 24(4), 392–400.
- Gini, C. (1912). Variabilità e mutabilità (variability and mutability). *Tipografia di Paolo Cuppini, Bologna, Italy*, 156.
- Goldenberg, R. L., Culhane, J. F., Iams, J. D., & Romero, R. (2008). Epidemiology and causes of preterm birth. *The lancet*, 371(9606), 75–84.
- Goodyear, M. D., Krleza-Jeric, K., & Lemmens, T. (2007). *The declaration of helsinki* (Vol. 335) (No. 7621). British Medical Journal Publishing Group.
- Haffajee, A., Teles, R., & Socransky, S. (2006). Association of eubacterium nodatum and treponema

- 903 denticola with human periodontitis lesions. *Oral microbiology and immunology*, 21(5), 269–282.
- 904 Hajishengallis, G. (2015). Periodontitis: from microbial immune subversion to systemic inflammation.
905 *Nature reviews immunology*, 15(1), 30–44.
- 906 Hamming, R. W. (1950). Error detecting and error correcting codes. *The Bell system technical journal*,
907 29(2), 147–160.
- 908 Han, Y. W. (2015). Fusobacterium nucleatum: a commensal-turned pathogen. *Current opinion in
909 microbiology*, 23, 141–147.
- 910 Han, Y. W., & Wang, X. (2013). Mobile microbiome: oral bacteria in extra-oral infections and
911 inflammation. *Journal of dental research*, 92(6), 485–491.
- 912 Hartstra, A. V., Bouter, K. E., Bäckhed, F., & Nieuwdorp, M. (2015). Insights into the role of the
913 microbiome in obesity and type 2 diabetes. *Diabetes care*, 38(1), 159–165.
- 914 Helmink, B. A., Khan, M. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019). The microbiome,
915 cancer, and cancer therapy. *Nature medicine*, 25(3), 377–388.
- 916 Hill, M. O. (1973). Diversity and evenness: a unifying notation and its consequences. *Ecology*, 54(2),
917 427–432.
- 918 Hiranmayi, K. V., Sirisha, K., Rao, M. R., & Sudhakar, P. (2017). Novel pathogens in periodontal
919 microbiology. *Journal of Pharmacy and Bioallied Sciences*, 9(3), 155–163.
- 920 Honda, K., & Littman, D. R. (2012). The microbiome in infectious disease and inflammation. *Annual
921 review of immunology*, 30(1), 759–795.
- 922 Honest, H., Forbes, C., Durée, K., Norman, G., Duffy, S., Tsourapas, A., ... others (2009). Screening to
923 prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with
924 economic modelling. *Health Technol Assess*, 13(43), 1–627.
- 925 Hong, Y. M., Lee, J., Cho, D. H., Jeon, J. H., Kang, J., Kim, M.-G., ... J. K. (2023). Predicting preterm
926 birth using machine learning techniques in oral microbiome. *Scientific Reports*, 13(1), 21105.
- 927 Huang, R.-Y., Lin, C.-D., Lee, M.-S., Yeh, C.-L., Shen, E.-C., Chiang, C.-Y., ... Fu, E. (2007). Mandibular
928 disto-lingual root: a consideration in periodontal therapy. *Journal of periodontology*, 78(8), 1485–
929 1490.
- 930 Iams, J. D., & Berghella, V. (2010). Care for women with prior preterm birth. *American journal of
931 obstetrics and gynecology*, 203(2), 89–100.
- 932 Ide, M., & Papapanou, P. N. (2013). Epidemiology of association between maternal periodontal
933 disease and adverse pregnancy outcomes—systematic review. *Journal of clinical periodontology*,
934 40, S181–S194.
- 935 Iniesta, M., Chamorro, C., Ambrosio, N., Marín, M. J., Sanz, M., & Herrera, D. (2023). Subgingival
936 microbiome in periodontal health, gingivitis and different stages of periodontitis. *Journal of
937 Clinical Periodontology*, 50(7), 905–920.
- 938 Janda, J. M., & Abbott, S. L. (2007). 16s rRNA gene sequencing for bacterial identification in the diagnostic
939 laboratory: pluses, perils, and pitfalls. *Journal of clinical microbiology*, 45(9), 2761–2764.
- 940 Jiang, W., & Simon, R. (2007). A comparison of bootstrap methods and an adjusted bootstrap approach
941 for estimating the prediction error in microarray classification. *Statistics in medicine*, 26(29),

- 942 5320–5334.
- 943 John, G. K., & Mullin, G. E. (2016). The gut microbiome and obesity. *Current oncology reports*, 18,
944 1–7.
- 945 Johnson, J. S., Spakowicz, D. J., Hong, B.-Y., Petersen, L. M., Demkowicz, P., Chen, L., ... others (2019).
946 Evaluation of 16s rrna gene sequencing for species and strain-level microbiome analysis. *Nature
947 communications*, 10(1), 5029.
- 948 Jorth, P., Turner, K. H., Gumus, P., Nizam, N., Buduneli, N., & Whiteley, M. (2014). Metatranscriptomics
949 of the human oral microbiome during health and disease. *MBio*, 5(2), 10–1128.
- 950 Karched, M., Bhardwaj, R. G., Qudeimat, M., Al-Khabbaz, A., & Ellepola, A. (2022). Proteomic analysis
951 of the periodontal pathogen prevotella intermedia secretomes in biofilm and planktonic lifestyles.
952 *Scientific Reports*, 12(1), 5636.
- 953 Katz, J., Chegini, N., Shiverick, K., & Lamont, R. (2009). Localization of p. gingivalis in preterm delivery
954 placenta. *Journal of dental research*, 88(6), 575–578.
- 955 Kelly, B. J., Gross, R., Bittinger, K., Sherrill-Mix, S., Lewis, J. D., Collman, R. G., ... Li, H. (2015).
956 Power and sample-size estimation for microbiome studies using pairwise distances and permanova.
957 *Bioinformatics*, 31(15), 2461–2468.
- 958 Kim, C. H. (2018). Immune regulation by microbiome metabolites. *Immunology*, 154(2), 220–229.
- 959 Kim, E.-H., Kim, S., Kim, H.-J., Jeong, H.-o., Lee, J., Jang, J., ... others (2020). Prediction of chronic
960 periodontitis severity using machine learning models based on salivary bacterial copy number.
961 *Frontiers in Cellular and Infection Microbiology*, 10, 571515.
- 962 Kim, J.-H. (2009). Estimating classification error rate: Repeated cross-validation, repeated hold-out and
963 bootstrap. *Computational statistics & data analysis*, 53(11), 3735–3745.
- 964 Kinane, D. F., Stathopoulou, P. G., & Papapanou, P. N. (2017). Periodontal diseases. *Nature reviews
965 Disease primers*, 3(1), 1–14.
- 966 Kindinger, L. M., Bennett, P. R., Lee, Y. S., Marchesi, J. R., Smith, A., Caciato, S., ... MacIntyre,
967 D. A. (2017). The interaction between vaginal microbiota, cervical length, and vaginal progesterone
968 treatment for preterm birth risk. *Microbiome*, 5, 1–14.
- 969 Kogut, M. H., Lee, A., & Santin, E. (2020). Microbiome and pathogen interaction with the immune
970 system. *Poultry science*, 99(4), 1906–1913.
- 971 Lafaurie, G. I., Neuta, Y., Ríos, R., Pacheco-Montealegre, M., Pianeta, R., Castillo, D. M., ... oth-
972 ers (2022). Differences in the subgingival microbiome according to stage of periodontitis: A
973 comparison of two geographic regions. *PloS one*, 17(8), e0273523.
- 974 Lamont, R. J., & Jenkinson, H. F. (2000). Subgingival colonization by porphyromonas gingivalis. *Oral
975 Microbiology and Immunology: Mini-review*, 15(6), 341–349.
- 976 Lamont, R. J., Koo, H., & Hajishengallis, G. (2018). The oral microbiota: dynamic communities and
977 host interactions. *Nature reviews microbiology*, 16(12), 745–759.
- 978 Leitich, H., & Kaider, A. (2003). Fetal fibronectin—how useful is it in the prediction of preterm birth?
979 *BJOG: An International Journal of Obstetrics & Gynaecology*, 110, 66–70.
- 980 León, R., Silva, N., Ovalle, A., Chaparro, A., Ahumada, A., Gajardo, M., ... Gamonal, J. (2007).

- 981 Detection of porphyromonas gingivalis in the amniotic fluid in pregnant women with a diagnosis
982 of threatened premature labor. *Journal of periodontology*, 78(7), 1249–1255.
- 983 Lim, J. W., Park, T., Tong, Y. W., & Yu, Z. (2020). The microbiome driving anaerobic digestion and
984 microbial analysis. In *Advances in bioenergy* (Vol. 5, pp. 1–61). Elsevier.
- 985 Lin, H., & Peddada, S. D. (2020). Analysis of compositions of microbiomes with bias correction. *Nature
986 communications*, 11(1), 3514.
- 987 Listgarten, M. A. (1986). Pathogenesis of periodontitis. *Journal of clinical periodontology*, 13(5),
988 418–425.
- 989 Lloyd-Price, J., Abu-Ali, G., & Huttenhower, C. (2016). The healthy human microbiome. *Genome
990 medicine*, 8, 1–11.
- 991 Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and dispersion for
992 rna-seq data with deseq2. *Genome biology*, 15, 1–21.
- 993 Magurran, A. E. (2021). Measuring biological diversity. *Current Biology*, 31(19), R1174–R1177.
- 994 Mann, H. B., & Whitney, D. R. (1947). On a test of whether one of two random variables is stochastically
995 larger than the other. *The annals of mathematical statistics*, 50–60.
- 996 Mayer, E. A., Tillisch, K., Gupta, A., et al. (2015). Gut/brain axis and the microbiota. *The Journal of
997 clinical investigation*, 125(3), 926–938.
- 998 Melguizo-Rodríguez, L., Costela-Ruiz, V. J., Manzano-Moreno, F. J., Ruiz, C., & Illescas-Montes, R.
999 (2020). Salivary biomarkers and their application in the diagnosis and monitoring of the most
1000 common oral pathologies. *International journal of molecular sciences*, 21(14), 5173.
- 1001 Miller, C. S., Ding, X., Dawson III, D. R., & Ebersole, J. L. (2021). Salivary biomarkers for discriminating
1002 periodontitis in the presence of diabetes. *Journal of clinical periodontology*, 48(2), 216–225.
- 1003 Morita, T., Yamazaki, Y., Mita, A., Takada, K., Seto, M., Nishinoue, N., ... Maeno, M. (2010). A cohort
1004 study on the association between periodontal disease and the development of metabolic syndrome.
1005 *Journal of periodontology*, 81(4), 512–519.
- 1006 Na, H. S., Kim, S. Y., Han, H., Kim, H.-J., Lee, J.-Y., Lee, J.-H., & Chung, J. (2020). Identification of
1007 potential oral microbial biomarkers for the diagnosis of periodontitis. *Journal of clinical medicine*,
1008 9(5), 1549.
- 1009 Nemoto, T., Shiba, T., Komatsu, K., Watanabe, T., Shimogishi, M., Shibasaki, M., ... others (2021).
1010 Discrimination of bacterial community structures among healthy, gingivitis, and periodontitis
1011 statuses through integrated metatranscriptomic and network analyses. *Msystems*, 6(6), e00886–21.
- 1012 Nesbitt, M. J., Reynolds, M. A., Shiau, H., Choe, K., Simonsick, E. M., & Ferrucci, L. (2010). Association
1013 of periodontitis and metabolic syndrome in the baltimore longitudinal study of aging. *Aging clinical
1014 and experimental research*, 22, 238–242.
- 1015 Nibali, L., Sousa, V., Davrandi, M., Spratt, D., Alyahya, Q., Dopico, J., & Donos, N. (2020). Differences
1016 in the periodontal microbiome of successfully treated and persistent aggressive periodontitis.
1017 *Journal of Clinical Periodontology*, 47(8), 980–990.
- 1018 Offenbacher, S., Katz, V., Fertik, G., Collins, J., Boyd, D., Maynor, G., ... Beck, J. (1996). Periodontal
1019 infection as a possible risk factor for preterm low birth weight. *Journal of periodontology*, 67,

- 1020 1103–1113.
- 1021 Papapanou, P. N., Sanz, M., Buduneli, N., Dietrich, T., Feres, M., Fine, D. H., ... others (2018).
1022 Periodontitis: Consensus report of workgroup 2 of the 2017 world workshop on the classification of
1023 periodontal and peri-implant diseases and conditions. *Journal of periodontology*, 89, S173–S182.
- 1024 Payne, M. S., Newnham, J. P., Doherty, D. A., Furfarro, L. L., Pendal, N. L., Loh, D. E., & Keelan, J. A.
1025 (2021). A specific bacterial dna signature in the vagina of australian women in midpregnancy
1026 predicts high risk of spontaneous preterm birth (the predict1000 study). *American journal of*
1027 *obstetrics and gynecology*, 224(2), 206–e1.
- 1028 Peirce, J. M., & Alviña, K. (2019). The role of inflammation and the gut microbiome in depression and
1029 anxiety. *Journal of neuroscience research*, 97(10), 1223–1241.
- 1030 Premaraj, T. S., Vella, R., Chung, J., Lin, Q., Hunter, P., Underwood, K., ... Zhou, Y. (2020). Ethnic
1031 variation of oral microbiota in children. *Scientific reports*, 10(1), 14788.
- 1032 Redanz, U., Redanz, S., Treerat, P., Prakasam, S., Lin, L.-J., Merritt, J., & Kreth, J. (2021). Differential
1033 response of oral mucosal and gingival cells to corynebacterium durum, streptococcus sanguinis, and
1034 porphyromonas gingivalis multispecies biofilms. *Frontiers in cellular and infection microbiology*,
1035 11, 686479.
- 1036 Relvas, M., Regueira-Iglesias, A., Balsa-Castro, C., Salazar, F., Pacheco, J., Cabral, C., ... Tomás, I.
1037 (2021). Relationship between dental and periodontal health status and the salivary microbiome:
1038 bacterial diversity, co-occurrence networks and predictive models. *Scientific reports*, 11(1), 929.
- 1039 Renson, A., Jones, H. E., Beghini, F., Segata, N., Zolnik, C. P., Usyk, M., ... others (2019). Sociodemo-
1040 graphic variation in the oral microbiome. *Annals of epidemiology*, 35, 73–80.
- 1041 Rideout, J. R., Caporaso, G., Bolyen, E., McDonald, D., Baeza, Y. V., Alastuey, J. C., ... Sharma, K.
1042 (2018, December). *biocore/scikit-bio: scikit-bio 0.5.5: More compositional methods added*. Zenodo.
1043 Retrieved from <https://doi.org/10.5281/zenodo.2254379> doi: 10.5281/zenodo.2254379
- 1044 Rôças, I. N., Siqueira Jr, J. F., Santos, K. R., Coelho, A. M., & de Janeiro, R. (2001). “red com-
1045 plex”(bacteroides forsythus, porphyromonas gingivalis, and treponema denticola) in endodontic
1046 infections: a molecular approach. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology,*
1047 *and Endodontology*, 91(4), 468–471.
- 1048 Romero, R., Dey, S. K., & Fisher, S. J. (2014). Preterm labor: one syndrome, many causes. *Science*,
1049 345(6198), 760–765.
- 1050 Romero, R., Hassan, S. S., Gajer, P., Tarca, A. L., Fadrosh, D. W., Nikita, L., ... others (2014). The
1051 composition and stability of the vaginal microbiota of normal pregnant women is different from
1052 that of non-pregnant women. *Microbiome*, 2, 1–19.
- 1053 Rosan, B., & Lamont, R. J. (2000). Dental plaque formation. *Microbes and infection*, 2(13), 1599–1607.
- 1054 Schwabe, R. F., & Jobin, C. (2013). The microbiome and cancer. *Nature Reviews Cancer*, 13(11),
1055 800–812.
- 1056 Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021). The
1057 microbiome and human cancer. *Science*, 371(6536), eabc4552.
- 1058 Sharma, S., & Tripathi, P. (2019). Gut microbiome and type 2 diabetes: where we are and where to go?

- 1059 *The Journal of nutritional biochemistry*, 63, 101–108.
- 1060 Simpson, E. (1949). Measurement of diversity. *Nature*, 163.
- 1061 Sotiriadis, A., Papatheodorou, S., Kavvadias, A., & Makrydimas, G. (2010). Transvaginal cervical
1062 length measurement for prediction of preterm birth in women with threatened preterm labor: a
1063 meta-analysis. *Ultrasound in Obstetrics and Gynecology: The Official Journal of the International
1064 Society of Ultrasound in Obstetrics and Gynecology*, 35(1), 54–64.
- 1065 Spss, I., et al. (2011). Ibm spss statistics for windows, version 20.0. *New York: IBM Corp*, 440, 394.
- 1066 Stafford, G., Roy, S., Honma, K., & Sharma, A. (2012). Sialic acid, periodontal pathogens and tannerella
1067 forsythia: stick around and enjoy the feast! *Molecular Oral Microbiology*, 27(1), 11–22.
- 1068 Stout, M. J., Conlon, B., Landeau, M., Lee, I., Bower, C., Zhao, Q., ... Mysorekar, I. U. (2013).
1069 Identification of intracellular bacteria in the basal plate of the human placenta in term and preterm
1070 gestations. *American journal of obstetrics and gynecology*, 208(3), 226–e1.
- 1071 Tanner, A. C., Kent Jr, R., Kanasi, E., Lu, S. C., Paster, B. J., Sonis, S. T., ... Van Dyke, T. E. (2007).
1072 Clinical characteristics and microbiota of progressing slight chronic periodontitis in adults. *Journal
1073 of clinical periodontology*, 34(11), 917–930.
- 1074 Tanner, A. C., Paster, B. J., Lu, S. C., Kanasi, E., Kent Jr, R., Van Dyke, T., & Sonis, S. T. (2006).
1075 Subgingival and tongue microbiota during early periodontitis. *Journal of dental research*, 85(4),
1076 318–323.
- 1077 Teles, F., Wang, Y., Hajishengallis, G., Hasturk, H., & Marchesan, J. T. (2021). Impact of systemic
1078 factors in shaping the periodontal microbiome. *Periodontology 2000*, 85(1), 126–160.
- 1079 Thaiss, C. A., Zmora, N., Levy, M., & Elinav, E. (2016). The microbiome and innate immunity. *Nature*,
1080 535(7610), 65–74.
- 1081 Tilg, H., Kaser, A., et al. (2011). Gut microbiome, obesity, and metabolic dysfunction. *The Journal of
1082 clinical investigation*, 121(6), 2126–2132.
- 1083 Tonetti, M. S., Greenwell, H., & Kornman, K. S. (2018). Staging and grading of periodontitis: Framework
1084 and proposal of a new classification and case definition. *Journal of periodontology*, 89, S159–S172.
- 1085 Tringe, S. G., & Hugenholtz, P. (2008). A renaissance for the pioneering 16s rrna gene. *Current opinion
1086 in microbiology*, 11(5), 442–446.
- 1087 Tucker, C. M., Cadotte, M. W., Carvalho, S. B., Davies, T. J., Ferrier, S., Fritz, S. A., ... others (2017). A
1088 guide to phylogenetic metrics for conservation, community ecology and macroecology. *Biological
1089 Reviews*, 92(2), 698–715.
- 1090 Ursell, L. K., Metcalf, J. L., Parfrey, L. W., & Knight, R. (2012). Defining the human microbiome.
1091 *Nutrition reviews*, 70(suppl_1), S38–S44.
- 1092 Vander Haar, E. L., So, J., Gyamfi-Bannerman, C., & Han, Y. W. (2018). Fusobacterium nucleatum and
1093 adverse pregnancy outcomes: epidemiological and mechanistic evidence. *Anaerobe*, 50, 55–59.
- 1094 Van der Maaten, L., & Hinton, G. (2008). Visualizing data using t-sne. *Journal of machine learning
1095 research*, 9(11).
- 1096 Weaver, W. (1963). *The mathematical theory of communication*. University of Illinois Press.
- 1097 Whiteside, S. A., Razvi, H., Dave, S., Reid, G., & Burton, J. P. (2015). The microbiome of the urinary

- 1098 tract—a role beyond infection. *Nature Reviews Urology*, 12(2), 81–90.
- 1099 Witkin, S. (2019). Vaginal microbiome studies in pregnancy must also analyse host factors. *BJOG: An*
1100 *International Journal of Obstetrics & Gynaecology*, 126(3), 359–359.
- 1101 Wong, T.-T., & Yeh, P.-Y. (2019). Reliable accuracy estimates from k-fold cross validation. *IEEE*
1102 *Transactions on Knowledge and Data Engineering*, 32(8), 1586–1594.
- 1103 Wyss, C., Moter, A., Choi, B.-K., Dewhirst, F., Xue, Y., Schüpbach, P., ... Guggenheim, B. (2004).
1104 Treponema putidum sp. nov., a medium-sized proteolytic spirochaete isolated from lesions of
1105 human periodontitis and acute necrotizing ulcerative gingivitis. *International journal of systematic*
1106 *and evolutionary microbiology*, 54(4), 1117–1122.
- 1107 Yaman, E., & Subasi, A. (2019). Comparison of bagging and boosting ensemble machine learning methods
1108 for automated emg signal classification. *BioMed research international*, 2019(1), 9152506.
- 1109 Yang, I., Claussen, H., Arthur, R. A., Hertzberg, V. S., Geurs, N., Corwin, E. J., & Dunlop, A. L. (2022).
1110 Subgingival microbiome in pregnancy and a potential relationship to early term birth. *Frontiers in*
1111 *cellular and infection microbiology*, 12, 873683.
- 1112 Yoshimura, F., Murakami, Y., Nishikawa, K., Hasegawa, Y., & Kawaminami, S. (2009). Surface
1113 components of porphyromonas gingivalis. *Journal of periodontal research*, 44(1), 1–12.
- 1114 Zhang, C.-Z., Cheng, X.-Q., Li, J.-Y., Zhang, P., Yi, P., Xu, X., & Zhou, X.-D. (2016). Saliva in the
1115 diagnosis of diseases. *International journal of oral science*, 8(3), 133–137.
- 1116 Zhu, W., & Lee, S.-W. (2016). Surface interactions between two of the main periodontal pathogens:
1117 *Porphyromonas gingivalis* and *tannerella forsythia*. *Journal of periodontal & implant science*,
1118 46(1), 2–9.
- 1119 Zhu, X., Han, Y., Du, J., Liu, R., Jin, K., & Yi, W. (2017). Microbiota-gut-brain axis and the central
1120 nervous system. *Oncotarget*, 8(32), 53829.

1121

Acknowledgments

1122 I would like to disclose my earnest appreciation for my advisor, Professor Semin Lee, who provided
 1123 solicitous supervision and cherished opportunities throughout the course of my research. His advice and
 1124 consultation encouraged me to become as a researcher and to receive all humility and gentleness. I am
 1125 also grateful to all of my committee members, Professor AAA, Professor BBB, Professor CCC, and
 1126 Professor DDD, for their critical and meaningful mentions and suggestions.

1127 I extend my deepest gratitude to my Lord, *the Flying Spaghetti Monster*, His Noodly Appendage
 1128 has guided me through the twist and turns of this academic journey. His presence, ever comforting and
 1129 mysterious, has been a source of strength and humor during both highs and lows. In moments of doubt, I
 1130 found solace in the belief that you were there, gently reminding me to keep faith in the process. His Holy
 1131 Noodle has nourished my mind, and for that, I am truly overwhelmed. May His Holy Noodle continue to
 1132 guide me in all my future endeavors. R’Amen.

1133 (Professors)

1134 I would like to extend my heartfelt gratitude to my colleagues of the Computational Biology Lab @
 1135 UNIST, whose collaboration, friendship, brotherhood, and support have been an invaluable part of my
 1136 journey. Your willingness to share insights, engage in thoughtful discussions, and offer encouragement
 1137 during the challenging moments of research has significantly shaped my academic experience. The
 1138 camaraderie in Computational Biology Lab made even the most demanding days more enjoyable, and I
 1139 am deeply grateful for the collaborative environment we created together. I appreciate you for standing
 1140 by my side throughout this Ph.D. journey.

1141 I would like to express my heartfelt gratitude to my family, whose unwavering support has been the
 1142 foundation of everything I have achieved. Your love, encouragement, and belief in me have sustained me
 1143 through every challenge, and I could not have come this far without you. From your words of wisdom to
 1144 your patience and understanding, each of you has played a vital role in helping me navigate this journey.
 1145 The strength and comfort I have drawn from our family bond have been my greatest source of resilience.
 1146 Your presence, both near and far, has filled my life with warmth and motivation. I am deeply grateful for
 1147 your unconditional love and for always being there when I needed you the most. Thank you for being my
 1148 constant source of strength and inspiration.

1149 I am incredibly pleased to my friends, especially my GSHS alumni (○망특), for their unwavering
 1150 support and encouragement throughout this journey. The bonds we formed back in our school days have
 1151 only grown stronger over the years, and I am fortunate to have had such loyal and understanding friends
 1152 by my side. Your constant words of motivation, and even moments of levity during stressful times have
 1153 helped keep me grounded. Whether it was a late-night conversations, a shared laugh, or a simple message
 1154 of reassurance, you all have played a vital role in keeping me focused and motivated. I am relieved for the
 1155 ways you celebrated each small achievement with me and how you patiently listened to my worries. The
 1156 memories of our shared past provided me with comfort and a sense of stability when the road ahead felt
 1157 uncertain. I could not have reached this point without the love and friendship that you all have generously
 1158 given. Each of your, in your unique way, has contributed to this dissertation, even if indirectly, and for

1159 that, I am forever beholden. I look forward to continuing our friendship as we all grow in our individual
1160 paths, knowing that the support we share is something truly special.

1161 (Girlfriend)

1162 I would like to express my sincere gratitude to the amazing members of my animal protection groups,
1163 DRDR (두루두루) and UNIMALS (유니멀스), whose dedication and compassion have been a constant
1164 source of motivation. Your unwavering commitment to improving the lives of animals has inspired me
1165 throughout this journey. I am also thankful for the beautiful cats we have cared for, whose presence
1166 brought both joy and purpose to our allegiance. Their playful spirits and gentle companionship served as
1167 daily reminders of why we continue to fight for animal rights. The bond we share, both with each other
1168 and with the animals we protect, has enriched my life in countless ways. I appreciate you all again for
1169 your support, dedication, and for being part of this meaningful cause.

1170 I would like to express my deepest gratitude to everyone I have had the honor of meeting throughout
1171 this journey. Your kindness, encouragement, and support have carried me through both the challenging
1172 and rewarding moments of my life. Whether through a kind word, thoughtful advice, or simply being
1173 there when I needed it most, your presence has made all the difference. I am incredibly fortunate to have
1174 received such generosity and warmth from those around me, and I do not take it for granted. Every act
1175 of kindness, no matter how big or small, has been a source of strength and motivation for me. To all
1176 my friends, colleagues, mentors, and beloved ones, thank you for your unwavering support. I am truly
1177 grateful for each of you, and your kindness has left an indelible mark on my journey.

1178 My Lord, *the Flying Spaghetti Monster*,
1179 give us grace to accept with serenity the things that cannot be changed,
1180 courage to change the things that should be changed,
1181 and the wisdom to distinguish the one from the other.

1182
1183 Glory be to *the Meatball*, to *the Sauce*, and to *the Holy Noodle*.
1184 As it was in the beginning, is now, and ever shall be.

1185 R'Amen.



May your progress be evident to all

